<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Deferasirox for managing transfusional iron overload in people with sickle cell disease - Meerpohl, JJ - 2014 | Cochrane Library</title> <meta content="Deferasirox for managing transfusional iron overload in people with sickle cell disease - Meerpohl, JJ - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007477.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Deferasirox for managing transfusional iron overload in people with sickle cell disease - Meerpohl, JJ - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007477.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007477.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Deferasirox for managing transfusional iron overload in people with sickle cell disease" name="citation_title"/> <meta content="Joerg J Meerpohl" name="citation_author"/> <meta content="Medical Center – Univ. of Freiburg, Faculty of Medicine, Univ. of Freiburg" name="citation_author_institution"/> <meta content="meerpohl@cochrane.de" name="citation_author_email"/> <meta content="Lisa K Schell" name="citation_author"/> <meta content="Institute for Quality and Efficiency in Health Care (IQWiG)" name="citation_author_institution"/> <meta content="Gerta Rücker" name="citation_author"/> <meta content="Faculty of Medicine and Medical Center – University of Freiburg" name="citation_author_institution"/> <meta content="Edith Motschall" name="citation_author"/> <meta content="Medical Center ‐ University of Freiburg, Faculty of Medicine, University of Freiburg" name="citation_author_institution"/> <meta content="Nigel Fleeman" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Charlotte M Niemeyer" name="citation_author"/> <meta content="University Medical Center Freiburg" name="citation_author_institution"/> <meta content="Dirk Bassler" name="citation_author"/> <meta content="University Hospital Zurich and University of Zurich" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD007477.pub3" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/06/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007477.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007477.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007477.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anemia, Sickle Cell [blood, *therapy]; Benzoates [adverse effects, *therapeutic use]; Chelation Therapy [adverse effects, *methods]; Deferasirox; Deferoxamine [adverse effects, therapeutic use]; Erythrocyte Transfusion [adverse effects]; Ferritins [blood]; Iron Chelating Agents [adverse effects, *therapeutic use]; Iron Overload [*drug therapy, etiology]; Randomized Controlled Trials as Topic; Triazoles [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007477.pub3&amp;doi=10.1002/14651858.CD007477.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="kKvAiZoF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007477\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007477\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007477\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007477\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007477.pub3",title:"Deferasirox for managing transfusional iron overload in people with sickle cell disease",firstPublishedDate:"Jun 4, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007477.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007477.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007477.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007477.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007477.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007477.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007477.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007477.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007477.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007477.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1284 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007477.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/full#CD007477-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/full#CD007477-sec-0084"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/full#CD007477-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/full#CD007477-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/full#CD007477-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/full#CD007477-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/full#CD007477-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/full#CD007477-sec-0078"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/appendices#CD007477-sec-0089"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/table_n/CD007477StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/table_n/CD007477StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Deferasirox for managing transfusional iron overload in people with sickle cell disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/information#CD007477-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Joerg J Meerpohl</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/information#CD007477-cr-0003">Lisa K Schell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/information#CD007477-cr-0004">Gerta Rücker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/information#CD007477-cr-0005">Edith Motschall</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/information#CD007477-cr-0006">Nigel Fleeman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/information#CD007477-cr-0007">Charlotte M Niemeyer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007477.pub3/information#CD007477-cr-0008">Dirk Bassler</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/information/en#CD007477-sec-0096">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 June 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007477.pub3">https://doi.org/10.1002/14651858.CD007477.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007477-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007477-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007477-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007477-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007477-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007477-abs-0001" lang="en"> <section id="CD007477-sec-0001"> <h3 class="title" id="CD007477-sec-0001">Background</h3> <p>Sickle cell disease (SCD) is a group of genetic haemoglobin disorders, that occurs in about 2.2 per 1000 births worldwide. Increasingly, some people with SCD develop secondary iron overload due to occasional red blood cell transfusions or are on long‐term transfusion programmes for e.g. secondary stroke prevention. Iron chelation therapy can prevent long‐term complications. </p> <p>Deferoxamine and deferiprone have been found to be efficacious. However, questions exist about the effectiveness and safety of the newer oral chelator deferasirox. </p> </section> <section id="CD007477-sec-0002"> <h3 class="title" id="CD007477-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of oral deferasirox in people with SCD and secondary iron overload. </p> </section> <section id="CD007477-sec-0003"> <h3 class="title" id="CD007477-sec-0003">Search methods</h3> <p>We searched the Cystic Fibrosis &amp; Genetic Disorders Group's Haemoglobinopathies Trials Register: date of most recent search:13 March 2014. </p> <p>We searched MEDLINE, Embase, Biosis Previews, Web of Science, Derwent Drug File, XTOXLINE, EBMR and <i>The Cochrane Library</i>, respectively; date of most recent searches: 02 August 2013. </p> <p>We searched four trial registries: <a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a>; <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; <a href="http://www.who.int./ictrp/en/" target="_blank">www.who.int./ictrp/en/</a>; <a href="http://www.drks.de" target="_blank">www.drks.de</a>; date of most recent searches: 03 June 2013. </p> </section> <section id="CD007477-sec-0004"> <h3 class="title" id="CD007477-sec-0004">Selection criteria</h3> <p>Randomised controlled trials comparing deferasirox with no therapy or placebo or with another iron chelating treatment schedule. </p> </section> <section id="CD007477-sec-0005"> <h3 class="title" id="CD007477-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed risk of bias and extracted data. We contacted the corresponding study authors for additional information. </p> </section> <section id="CD007477-sec-0006"> <h3 class="title" id="CD007477-sec-0006">Main results</h3> <p>Two studies (with 203 and 212 people) comparing the efficacy and safety of deferasirox and deferoxamine after 12 months and 24 weeks, respectively, were included. The overall quality, according to GRADE, for the main outcomes was moderate to low. Only limited data were available on mortality and end‐organ damage, although one study did assess mortality, relative risk 1.26 (95% confidence interval 0.05 to 30.41), the 24‐week follow up was too short to allow us to draw firm conclusions. One study reported a relative risk of 1.26 for the incidence of type 2 diabetes mellitus (95% confidence interval 0.05 to 30.41). Serum ferritin reduction was significantly greater with deferoxamine, mean difference of change of 440.69 µg/l (95% confidence interval 11.73 to 869.64). Liver iron concentration (reported in one study) measured by superconduction quantum interference device showed no significant difference for the overall group of patients adjusted for transfusion category, mean difference ‐0.20 mg Fe/g dry weight (95% confidence interval ‐3.15 to 2.75). </p> <p>The occurrence of serious adverse events did not differ between drugs. Nausea, diarrhoea and rash occurred significantly more often in people treated with deferasirox, while adverse events of any kind were more often reported for patients treated with deferoxamine (one study). The mean increase of creatinine was also significantly higher with deferasirox, mean difference 3.24 (95% confidence interval 0.45 to 6.03). Long‐term adverse events could not be measured in the included studies (follow up 52 weeks and 24 weeks). Patient satisfaction and the likelihood of continuing treatment, were significantly better with deferasirox. </p> </section> <section id="CD007477-sec-0007"> <h3 class="title" id="CD007477-sec-0007">Authors' conclusions</h3> <p>Deferasirox appears to be of similar efficacy to deferoxamine depending on depending on the appropriate ratio of doses of deferoxamine and deferasirox being compared. However, only limited evidence is available assessing the efficacy regarding patient‐important outcomes. The short‐term safety of deferasirox seems to be acceptable, however, follow up in the available studies was too short to assess long‐term side effects. Long‐term safety and efficacy data are available from a non‐controlled extension phase not included in our review; however, no valid comparative conclusions can be drawn and future studies should assess comparatively long‐term outcomes both for safety and efficacy. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007477-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007477-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007477-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007477-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007477-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007477-abs-0002" lang="en"> <h3>Deferasirox for managing transfusional iron overload in people with sickle cell disease</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the effect of deferasirox on secondary iron load in people with sickle cell disease. </p> <p><b>Background</b> </p> <p>Sickle cell disease is a genetic disorder. An increasing number of people with this disorder show secondary iron overload (an accumulation of excess iron in the body) due to repeated red blood cell transfusions. Since the human body is not able to actively get rid of excessive iron, drug treatment (known as iron chelators) is needed. Several years ago, a new oral iron chelator, deferasirox, was introduced. However, it is not known whether deferasirox offers advantages compared to other iron chelators (deferoxamine or deferiprone) with regard to effectiveness and safety. </p> <p><b>Study characteristics</b> </p> <p>Two randomised studies, with moderate overall quality of evidence, comparing deferasirox to deferoxamine were identified. The evidence is current to 02 August 2013. The studies with 203 and 212 participants lasted for 12 months and 24 weeks, respectively. </p> <p><b>Key results</b> </p> <p>Only little data on patient‐important outcomes such as mortality (limited by a short study follow up) and end‐organ damage (incidence of diabetes mellitus) were available. Iron removal, as measured by the surrogate marker serum ferritin was significantly greater with deferoxamine. In one study, both drugs were reported to work equally well in reducing liver iron concentration. </p> <p>The safety of deferasirox was acceptable; the main side effects when compared to deferoxamine were increased frequency of nausea, diarrhoea and rash as well as a mean increase of creatinine, while adverse events of any kind were observed more often in people treated with deferoxamine. Patient satisfaction and compliance with therapy was significantly greater with deferasirox. </p> <p><b>Quality of the evidence</b> </p> <p>The overall quality of evidence rated according to the GRADE criteria was moderate due to issues with study design. For four outcomes, namely liver iron concentration, serum ferritin, creatinine increase and satisfaction with treatment, it was judged as 'moderate' quality; for one outcome (discontinuations) was judged as 'low' quality. </p> <p><b>Summary</b> </p> <p>In summary, the evidence from the two included studies suggests that deferasirox is similarly effective as deferoxamine depending on the appropriate ratio of doses of deferoxamine and deferasirox being compared. In the short term, deferasirox appears to have an acceptable safety profile, but there are no comparative data based on randomised controlled trials available looking at long‐term safety. Further data on long‐term efficacy on patient‐relevant outcomes and long‐term adverse effects are needed to decide whether deferasirox should be used as alternative to the first‐line option of deferoxamine. Currently, its use seems to be mainly warranted as a treatment option for people with sickle cell disease who cannot tolerate or comply with deferoxamine. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007477-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007477-sec-0084"></div> <h3 class="title" id="CD007477-sec-0085">Implications for practice</h3> <section id="CD007477-sec-0085"> <p>Deferasirox offers a new interesting option to the treatments available for secondary iron overload in people with sickle cell disease. It appears to be of similar efficacy as deferoxamine depending on the appropriate ratio of doses of deferoxamine and deferasirox being compared as chosen in the two randomised studies, or even higher, with regard to surrogate endpoints after 12 months and 24 weeks, respectively. Accordingly, it is now widely used due to its easier mode of application. The short‐term safety of deferasirox seems to be acceptable; however, follow up in the included studies was too short to evaluate comparative efficacy and long‐term side effects. Currently, only limited evidence on long‐term efficacy and safety is available from the extension phase of one trial following patients treated with deferasirox only. </p> <p>Even though there are no randomised trials looking at long‐term patient‐important outcomes in people with sickle cell disease on deferoxamine, there is long‐standing experience with this drug. Thus, for people faced with initiating iron chelating therapy, both treatment options should be discussed in detail. Advantages and disadvantages should be pointed out, taking account of the limited evidence on deferasirox, this should be followed by fully informed shared decision‐making. For people being well‐managed with deferoxamine, it does not seem to be necessary to change the regimen to deferasirox. For people experiencing intolerance to deferoxamine or with low compliance due to the laborious mode of application, deferasirox should be offered as an alternative. However, effort should be made to enrol these patients in clinical trials to further gain insight into the effects of deferasirox; if no randomised controlled trials enrolling patients are being conducted, observational data should be collected in surveillance studies to better monitor adverse events. </p> </section> <h3 class="title" id="CD007477-sec-0086">Implications for research</h3> <section id="CD007477-sec-0086"> <p>Further studies on the effects of deferasirox in people with sickle cell disease are needed for several reasons. Firstly, they need to overcome the limitations of the available two randomised controlled trials, namely short duration and limited data on patient‐relevant outcomes. Also, focusing on efficacy measures is of high importance. Furthermore, the producer of deferasirox sponsored not only the included studies in sickle cell disease, but also the aforementioned studies in other conditions, such as thalassaemia. In our opinion, investigator‐initiated studies designed and conducted independently from Novartis are desirable. Finally, further studies should be undertaken looking at, e.g. different dosing schemes or a combination of deferasirox with other iron chelators (or both) to establish the optimal treatment algorithm for individual patients based on their iron overload status. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007477-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007477-sec-0022"></div> <div class="table" id="CD007477-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Deferasirox versus deferoxamine for managing transfusional iron overload in people with sickle cell disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Deferasirox versus deferoxamine for managing transfusional iron overload in people with sickle cell disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with sickle cell disease and transfusional iron overload<br/> <b>Settings:</b> <br/> <b>Intervention:</b> deferasirox </p> <p><b>Comparison:</b> deferoxamine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Deferoxamine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Deferasirox</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> <br/> Follow up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not estimable (event rate in study 0/56)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not estimable (event rate in study 1/135)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> <br/> (0.05 to 30.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐organ damage (incidence of diabetes)</b> <br/> Follow up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not estimable (event rate in study 0/56)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not estimable (event rate in study 1/135)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> <br/> (0.05 to 30.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LIC measured by SQUID biomagnetometer (mg Fe/g dw); overall population adjusted for transfusion category</b> <br/> Follow up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean LIC measured by SQUID biomagnetometer (mg Fe/g dw) in the intervention group was <b>0.2 lower</b> (3.15 lower to 2.75 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum ferritin (µg/l)</b> <br/> Follow up: 24 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum ferritin (µg/l) in the intervention groups was<br/> <b>440.69 higher</b> <br/> (11.73 to 869.64 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>283<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AE:</b> Change in creatinine from baseline (µmol/l)<br/> Follow up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean creatinine change from baseline in the intervention group was <b>3.24 higher</b> (0.45 to 6.03 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Discontinuations</b> <br/> Follow up: 24 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>168 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> <br/> (52 to 155) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.53</b> <br/> (0.31 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>398<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction</b> <br/> Follow up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>238 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>745 per 1000</b> <br/> (474 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.13</b> <br/> (1.99 to 4.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AE</b> : adverse events; <b>CI:</b> confidence interval; <b>dw</b> : dry weight; <b>Fe</b> : iron; <b>LIC</b> : liver iron concentration; <b>RR:</b> risk ratio; <b>SQUID</b>: superconducting quantum interference device </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> No ITT analysis with regard to efficacy. Unclear risk of other bias due to involvement of sponsor and possibility of selective reporting. See also risk of bias table.<br/> <sup>2</sup> Mortality due to iron overload cannot be adequately assessed in studies with a maximum follow up of 52 weeks.<br/> <sup>3</sup> Wide 95% confidence interval.<br/> <sup>4</sup> Serious inconsistency with an I² of 77%. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007477-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007477-sec-0023"></div> <section id="CD007477-sec-0024"> <h3 class="title" id="CD007477-sec-0024">Description of the condition</h3> <p>Sickle cell disease (SCD) is an autosomal recessive genetic disorder caused by a single nucleotide mutation of the haemoglobin β‐chain. The worldwide birth rate of people who are homozygous or compound heterozygous for symptomatic SCD is about 2.2 per 1000 births (<a href="./references#CD007477-bbs2-0006" title="AngastiniotisM , ModellB . Global epidemiology of hemoglobin disorders. Annals of the New York Academy of Sciences1998;850:251‐69. ">Angastiniotis 1998</a>; <a href="./references#CD007477-bbs2-0059" title="ModellB , DarlisonM . Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization2008;86(6):480‐7. ">Modell 2008</a>). However, the incidence of this disease varies widely between ethnic groups (<a href="./references#CD007477-bbs2-0059" title="ModellB , DarlisonM . Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization2008;86(6):480‐7. ">Modell 2008</a>). Populations originating from sub‐Saharan Africa, the Middle East and parts of the Mediterranean are predominantly affected, but population movement has made SCD a worldwide problem. </p> <p>The inheritance of one mutated gene (substitution of valine for glutamic acid in the sixth position of the beta chain of the haemoglobin molecule) together with the normal gene for adult haemoglobin (HbA) results in a mutant protein giving rise to a defective variant of haemoglobin. People with the heterozygous state (HbAS or sickle cell trait) are called sickle cell carriers. They are asymptomatic and need neither treatment nor occupational restrictions. The heterozygous state gives some advantage to carriers against malaria infection and has therefore persisted (<a href="./references#CD007477-bbs2-0087" title="WeatherallDJ . Thalassemia in the next millennium. Keynote address. Annals of the New York Academy of Sciences1998;850:1‐9. ">Weatherall 1998</a>; <a href="./references#CD007477-bbs2-0073" title="RicherJ , ChudleyAE . The hemoglobinopathies and malaria. Clinical Genetics2005;68(4):332‐6. ">Richer 2005</a>). </p> <p>The homozygous state (HbSS) results from inheriting the mutation from both parents. Sickle cell disease can also occur when people are compound heterozygous by inheriting the sickle cell gene from one parent and another variant haemoglobin gene, such as haemoglobin C, D, OArab or E, or a β‐thalassaemia gene from the second parent. This gives rise to HbSC, HbSD, HbSOArab, HbSE or HbSβ+ or HbSβ0. All of these genotypes cause clinically significant SCD with chronic haemolytic anaemia and a predisposition to blockage of small blood vessels resulting in painful crises, acute chest syndrome, cerebral infarction and other complications due to the sickling of the red blood cells. However, the overall severity and patterns of organ damage vary widely depending upon genotype (<a href="./references#CD007477-bbs2-0069" title="PlattOS , ThoringtonBD , BrambillaDJ , MilnerPF , RosseWF , VichinskyE , et al. Pain in sickle cell disease. Rates and risk factors. New England Journal of Medicine1991;325(1):11‐6. ">Platt 1991</a>; <a href="./references#CD007477-bbs2-0057" title="MillerST , SleeperLA , PegelowCH , EnosLE , WangWC , WeinerSJ , et al. Prediction of adverse outcomes in children with sickle cell disease. New England Journal of Medicine2000;342(2):83‐9. ">Miller 2000</a>; <a href="./references#CD007477-bbs2-0070" title="PowarsDR , ChanLS , HitiA , RamiconeE , JohnsonC . Outcome of sickle cell anemia: a 4‐decade observational study of 1056 patients. Medicine (Baltimore)2005;84(6):363‐76. ">Powars 2005</a>). </p> <p>Unlike people with β‐thalassaemia major, who require regular blood transfusions throughout life from soon after birth, the majority of people with SCD require red cell transfusions only occasionally and intermittently. These are required for indications such as the management of acute severe anaemia in children, e.g. due to splenic sequestration or transient Parvovirus B19 induced aplastic crisis, acute chest syndrome, acute stroke or as a prophylactic measure before operations. Red cell transfusions are not usually required for the management of the chronic anaemia, or acute painful episodes (<a href="./references#CD007477-bbs2-0045" title="JosephsonCD , SuLL , HillyerKL , HillyerCD . Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfusion Medicine Reviews2007;21(2):118‐33. ">Josephson 2007</a>). By adulthood, the majority of people with SCD have received several red blood cell transfusions for various reasons. </p> <p>A small but increasing number of people with SCD are on long‐term transfusions, most commonly for secondary stroke prevention, but also for primary stroke prevention, or for recurrent pulmonary complications in people who have not responded to hydroxycarbamide. Over the last decade trials have evaluated the effect of regular prophylactic transfusions for the primary prevention of stroke in children with SCD (<a href="./references#CD007477-bbs2-0004" title="AdamsRJ , McKieVC , HsuL , FilesB , VichinskyE , PegelowC , et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. New England Journal of Medicine1998;339(1):5‐11. ">Adams 1998</a>; <a href="./references#CD007477-bbs2-0005" title="AdamsRJ , BrambillaD . Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. New England Journal of Medicine2005;353(26):2769‐78. ">Adams 2005</a>). Trans‐cranial doppler (TCD) screening is now recommended as routine care. High‐risk children are identified by high‐flow velocities on TCDs and should be offered long‐term transfusion therapy. </p> <p>Since the body has no physiological mechanism to actively excrete excess iron, repeated blood transfusions lead to an increased body iron burden including iron deposition into the liver, heart, pancreas and other endocrine organs. This mechanism is well known for people with thalassaemia on regular transfusion programs. As studies have shown, people with SCD with repeated blood transfusions can be affected by the same long‐term problems due to iron overload (<a href="./references#CD007477-bbs2-0076" title="VichinskyE , ButenskyE , FungE , HudesM , TheilE , FerrellL , et al. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. American Journal of Hematology2005;80(1):70‐4. ">Vichinsky 2005a</a>). Even if there is no solid evidence showing that iron chelation improves clinical outcome in SCD, iron chelation therapy is generally offered to iron‐overloaded people with SCD. </p> </section> <section id="CD007477-sec-0025"> <h3 class="title" id="CD007477-sec-0025">Description of the intervention</h3> <p>Deferoxamine (DFO, Desferal<sup>®</sup>), reviewed in detail in a Cochrane Review (<a href="./references#CD007477-bbs2-0032" title="FisherSA , BrunskillSJ , DoreeC , GoodingS , ChowdhuryO , RobertsDJ . Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion‐dependent thalassaemia. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD004450.pub3] ">Fisher 2013a</a>), has been the treatment of choice for iron overload for the last 40 years. Since it has been available for a long time it is the only chelating agent for which a profound effect on the long‐term survival of a large cohort of patients with thalassaemia has been shown (<a href="./references#CD007477-bbs2-0093" title="ZurloMG , DeStefanoP , Borgna‐PignattiC , DiPalmaA , PigaA , MelevendiC , et al. Survival and causes of death in thalassaemia major. Lancet1989;2(8653):27‐30. ">Zurlo 1989</a>; <a href="./references#CD007477-bbs2-0010" title="BrittenhamGM , GriffithPM , NienhuisAW , McLarenCE , YoungNS , TuckerEE , et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. New England Journal of Medicine1994;331(9):567‐73. ">Brittenham 1994</a>; <a href="./references#CD007477-bbs2-0035" title="GabuttiV , PigaA . Results of long‐term iron‐chelating therapy. Acta Haematologica1996;95(1):26‐36. ">Gabutti 1996</a>; <a href="./references#CD007477-bbs2-0008" title="Borgna‐PignattiC , RugolottoS , DeStefanoP , ZhaoH , CappelliniMD , DelVecchioGC , et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica2004;89(10):1187‐93. ">Borgna‐Pignatti 2004</a>). To be clinically effective deferoxamine has to be administered as a subcutaneous infusion over 8 to 12 hours, five to seven days per week. This regimen has been demonstrated to reduce the body iron load, prevent the onset of iron‐induced complications and even reverse some of the organ‐damage due to iron (<a href="./references#CD007477-bbs2-0061" title="OlivieriNF , NathanDG , MacMillanJH , WayneAS , LiuPP , McGeeA , et al. Survival in medically treated patients with homozygous beta‐thalassemia. New England Journal of Medicine1994;331(9):574‐8. ">Olivieri 1994</a>). But the arduous schedule of overnight subcutaneous infusions often leads to reduced compliance (<a href="./references#CD007477-bbs2-0062" title="OlivieriNF , BrittenhamGM . Iron‐chelating therapy and the treatment of thalassemia. Blood1997;89(3):739‐61. ">Olivieri 1997</a>; <a href="./references#CD007477-bbs2-0058" title="ModellB , KhanM , DarlisonM . Survival in beta‐thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet2000;355(9220):2051‐2. ">Modell 2000</a>; <a href="./references#CD007477-bbs2-0012" title="CappelliniMD . Overcoming the challenge of patient compliance with iron chelation therapy. Seminars in Hematology2005;42(2 Suppl 1):S19‐21. ">Cappellini 2005</a>). Another problem concerns the toxicity of deferoxamine, particularly at higher doses. Toxicities beside local skin reactions include ophthalmologic (optic neuropathy, retinal pigmentation) and hearing problems (high frequency sensorineural hearing loss). Rare adverse effects like growth retardation, renal impairment (<a href="./references#CD007477-bbs2-0052" title="KorenG , Kochavi‐AtiyaY , BenturY , OlivieriNF . The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. International Journal of Hematology1991;54(5):371‐5. ">Koren 1991</a>), anaphylactic reactions and pulmonary fibrosis (<a href="./references#CD007477-bbs2-0034" title="FreedmanMH , GrisaruD , OlivieriN , MacLuskyI , ThornerPS . Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. American Journal of Diseases of Children1990;144(5):565‐9. ">Freedman 1990</a>) have been reported. The high cost (about $US 10,000 a year) of deferoxamine (<a href="./references#CD007477-bbs2-0026" title="DeleaTE , HagiwaraM , ThomasSK , BaladiJF , PhatakPD , CoatesTD . Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. American Journal of Hematology2008;83(4):263‐70. ">Delea 2008</a>) and the consumables required as well as its complicated mode of administration limit its use in developing countries. </p> <p>Oral preparations have been highly sought after for many years. In 1987 two studies showed that the orally active iron chelator deferiprone (1,2 dimethyl‐3‐hydroxypyrid‐4‐1, also known as L1, CP20, Ferriprox<sup>®</sup> or Kelfer) could achieve effective short‐term iron chelation (<a href="./references#CD007477-bbs2-0049" title="KontoghiorghesGJ , AldouriMA , HoffbrandAV , BarrJ , WonkeB , KourouclarisT , et al. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one. BMJ (Clinical Research Edition)1987;295(6612):1509‐12. ">Kontoghiorghes 1987a</a>; <a href="./references#CD007477-bbs2-0050" title="KontoghiorghesGJ , AldouriMA , SheppardL , HoffbrandAV . 1,2‐Dimethyl‐3‐hydroxypyrid‐4‐one, an orally active chelator for treatment of iron overload. Lancet1987;1(8545):1294‐5. ">Kontoghiorghes 1987b</a>). Doubts on the efficacy to reduce liver iron and prevent liver damage arose due to individuals with progression to overt liver fibrosis (<a href="./references#CD007477-bbs2-0063" title="OlivieriNF , BrittenhamGM , McLarenCE , TempletonDM , CameronRG , McClellandRA , et al. Long‐term safety and effectiveness of iron‐chelation therapy with deferiprone for thalassemia major. New England Journal of Medicine1998;339(7):417‐23. ">Olivieri 1998</a>). The hypothesis of direct liver toxicity of deferiprone could not be confirmed though (<a href="./references#CD007477-bbs2-0086" title="WanlessIR , SweeneyG , DhillonAP , GuidoM , PigaA , GalanelloR , et al. Lack of progressive hepatic fibrosis during long‐term therapy with deferiprone in subjects with transfusion‐dependent beta‐thalassemia. Blood2002;100(5):1566‐9. ">Wanless 2002</a>; <a href="./references#CD007477-bbs2-0091" title="WuSF , PengCT , WuKH , TsaiCH . Liver fibrosis and iron levels during long‐term deferiprone treatment of thalassemia major patients. Hemoglobin2006;30(2):215‐8. ">Wu 2006</a>). Several studies have shown in the meantime the efficacy of deferiprone for iron chelation (<a href="./references#CD007477-bbs2-0020" title="CeciA , BaiardiP , FelisiM , CappelliniMD , CarnelliV , DeS , et al. The safety and effectiveness of deferiprone in a large‐scale, 3‐year study in Italian patients. British Journal of Haematology2002;118(1):330‐6. ">Ceci 2002</a>; <a href="./references#CD007477-bbs2-0055" title="MaggioA , D'AmicoG , MorabitoA , CapraM , CiaccioC , CianciulliP , et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells, Molecules &amp; Diseases2002;28(2):196‐208. ">Maggio 2002</a>) and in particular its benefit on cardiac iron and cardiac morbidity (<a href="./references#CD007477-bbs2-0066" title="PengCT , TsaiCH , WuKH . Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience. Hemoglobin2008;32(1‐2):49‐62. ">Peng 2008</a>). However, its use has been quite limited, mainly as second‐line therapy, due to its range of adverse effects (<a href="./references#CD007477-bbs2-0044" title="HoffbrandAV , CohenA , HershkoC . Role of deferiprone in chelation therapy for transfusional iron overload. Blood2003;102(1):17‐24. ">Hoffbrand 2003</a>). These include gastrointestinal disturbances, arthropathy, neutropenia and agranulocytosis (<a href="./references#CD007477-bbs2-0043" title="HoffbrandAV , BartlettAN , VeysPA , O'ConnorNT , KontoghiorghesGJ . Agranulocytosis and thrombocytopenia in patient with Blackfan‐Diamond anaemia during oral chelator trial. Lancet1989;2(8660):457. ">Hoffbrand 1989</a>). Recently studies on combination therapy with synergistic effects of deferoxamine and deferiprone have been performed (<a href="./references#CD007477-bbs2-0046" title="KattamisA , KassouC , BerdousiH , LadisV , PapassotiriouI , KattamisC . Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica2003;88(12):1423‐5. ">Kattamis 2003</a>; <a href="./references#CD007477-bbs2-0064" title="OrigaR , BinaP , AgusA , CrobuG , DefraiaE , DessiC , et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica2005;90(10):1309‐14. ">Origa 2005</a>; <a href="./references#CD007477-bbs2-0030" title="FarmakiK , AngelopoulosN , AnagnostopoulosG , GotsisE , RombopoulosG , TolisG . Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta‐thalassaemia major. British Journal of Haematology2006;134(4):438‐44. ">Farmaki 2006</a>; <a href="./references#CD007477-bbs2-0036" title="GalanelloR , KattamisA , PigaA , FischerR , LeoniG , LadisV , et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica2006;91(9):1241‐3. ">Galanello 2006</a>; <a href="./references#CD007477-bbs2-0074" title="TannerMA , GalanelloR , DessiC , SmithGC , WestwoodMA , AgusA , et al. A randomized, placebo‐controlled, double‐blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation2007;115(14):1876‐84. ">Tanner 2007</a>; <a href="./references#CD007477-bbs2-0048" title="KolnagouA , EconomidesC , EracleousE , KontoghiorghesGJ . Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin2008;32(1‐2):41‐7. ">Kolnagou 2008</a>). An excellent Cochrane Review on the effectiveness of deferiprone in people with thalassaemia has recently been published (<a href="./references#CD007477-bbs2-0033" title="FisherSA , BrunskillSJ , DoreeC , ChowdhuryO , GoodingS , RobertsDJ . Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD004839.pub3] ">Fisher 2013b</a>). </p> </section> <section id="CD007477-sec-0026"> <h3 class="title" id="CD007477-sec-0026">How the intervention might work</h3> <p>Deferasirox (4‐[3,5‐bis(2‐hydroxyphenyl)‐1H‐1,2,4‐triazol‐1‐yl]‐benzoic acid) also known as CGP 72670, ICL670 or Exjade<sup>®</sup> is a new oral chelator available for routine use. It is approved for the treatment of secondary iron overload by the US Food and Drug Administration (FDA) (<a href="./references#CD007477-bbs2-0031" title="Food , Drug Administration(FDA) . USA . Exjade. www.fda.gov/cder/foi/label/2007/021882s002lbl/pdf (accessed 14 February 2008). ">FDA 2005</a>) and the European Medicines Agency (EMEA) (<a href="./references#CD007477-bbs2-0029" title="European Medicines Agency, London , UK . Exjade: European Public Assessment Report: Summary of Product Characteristics. www.emea.europa.eu/humandocs/Humans/EPAR/exjade/exjade.htm (accessed 14 February 2008). ">EMEA 2007</a>). It is rapidly absorbed after administration and has a bioavailability of about 70%. Safety and tolerability were shown in a randomised dose escalation trial in people with β‐thalassaemia in 2003 (<a href="./references#CD007477-bbs2-0060" title="Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. ">Nisbet‐Brown 2003</a>). The elimination half‐life of 8 to 16 hours allows a once‐daily administration after the tablets have been added to water or juice. Being a tridentate chelator two molecules of deferasirox are needed to bind one molecule of iron. The excretion of the bound iron is mainly via faeces. </p> <p>Adverse effects known from experiences in people with thalassaemia include gastrointestinal disturbances (nausea, stomach pain or diarrhoea) that are generally mild and a diffuse rash being more common at higher doses (<a href="./references#CD007477-bbs2-0013" title="CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. [PUBMED: 16352812] ">Cappellini 2006</a>). More rarely, fever, headache and cough are encountered. The main adverse effect with the use of deferasirox seems to be a mild to moderate elevation of the creatinine level in about a third of patients. Elevations of liver enzyme levels have also been described with a lower incidence (5.6%) (<a href="./references#CD007477-bbs2-0013" title="CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. [PUBMED: 16352812] ">Cappellini 2006</a>). As with standard therapy (deferoxamine), hearing loss and ocular disturbances including cataracts and retinal disorders have been reported with a very low incidence (&lt; 1%). </p> </section> <section id="CD007477-sec-0027"> <h3 class="title" id="CD007477-sec-0027">Why it is important to do this review</h3> <p>Deferoxamine necessitates a serious commitment from the user and due to its adverse effects deferiprone is only approved as second line therapy in some countries. Thus, much hope is being placed in the newer oral chelator deferasirox which ‐ as studies in people with thalassaemia have shown ‐ apparently offers a promising line of treatment due to its iron chelation properties and safety and tolerability profile (<a href="./references#CD007477-bbs2-0060" title="Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. ">Nisbet‐Brown 2003</a>; <a href="./references#CD007477-bbs2-0013" title="CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. [PUBMED: 16352812] ">Cappellini 2006</a>; <a href="./references#CD007477-bbs2-0067" title="PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2006</a>; <a href="./references#CD007477-bbs2-0014" title="CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. [PUBMED: 17697909] ">Cappellini 2007a</a>). Although these results are presumably generalisable to people with SCD, a thorough evaluation of deferasirox in people with SCD seems to be warranted. To adequately manage the increasing number of people with SCD being regularly transfused due to TCD screening results, a systematic review of the effectiveness and safety of deferasirox looking at people with SCD according to Cochrane standards is needed. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007477-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007477-sec-0028"></div> <p>To evaluate the effectiveness and safety of oral deferasirox for management of transfusional iron overload in people with SCD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007477-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007477-sec-0029"></div> <section id="CD007477-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007477-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) were considered for this review.</p> </section> <section id="CD007477-sec-0032"> <h4 class="title">Types of participants</h4> <p>People with SCD (irrespective of genotype, age and from any setting worldwide), who have received repeated red blood cell transfusions in the past or who are receiving regular red blood cell transfusions currently which have resulted in iron overload (defined as ferritin levels of over 1000 ng/ml on at least two occasions). </p> </section> <section id="CD007477-sec-0033"> <h4 class="title">Types of interventions</h4> <p>For oral deferasirox (all schedules and doses), the following comparisons are conceivable:</p> <p> <ol id="CD007477-list-0001"> <li> <p>deferasirox compared with no therapy or placebo;</p> </li> <li> <p>deferasirox compared with another iron chelating treatment schedule (i.e. deferoxamine or deferiprone or any combination thereof). </p> </li> </ol> </p> <p>These comparisons constitute two separate groups and would have been analysed separately. However, the necessity of chelation therapy in iron‐overloaded people is well‐established and, if at all, only short‐term, e.g. pharmacokinetic studies would be ethically justifiable. Longer‐term studies with no therapy or placebo would not suffice the paradigm of equipoise and we did not expect to find, and in fact did not find, any studies comparing deferasirox to no therapy or placebo. </p> </section> <section id="CD007477-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD007477-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD007477-list-0002"> <li> <p>Time to death (any cause)</p> </li> </ol> </p> </section> <section id="CD007477-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD007477-list-0003"> <li> <p>Reduced end‐organ damage due to iron deposition</p> <ol id="CD007477-list-0004"> <li> <p>cardiac failure (necessitating medical treatment)</p> </li> <li> <p>endocrine disease (necessitating substitution hormone therapy or treatment of diabetes)</p> </li> <li> <p>histological evidence of hepatic fibrosis</p> </li> <li> <p>pathological surrogate markers of end‐organ damage (i.e. elevated liver enzymes, elevated fasting glucose or pathological oral glucose tolerance test (OGTT), pathological measures (e.g. ejection fraction) in echocardiography) </p> </li> </ol> </li> <li> <p>Measures of iron overload</p> <ol id="CD007477-list-0005"> <li> <p>serum ferritin (ng/ml)</p> </li> <li> <p>iron levels in biopsies of liver and other tissue (mg/g liver dry weight)</p> </li> <li> <p>tissue iron assessment by SQUID (superconducting quantum interference device) (mg/g liver wet weight) </p> </li> <li> <p>tissue iron assessment by MRI (magnetic resonance imaging) (ms)</p> </li> </ol> </li> <li> <p>Measures of iron excretion (urine and faeces) over 24 hours (mg/kg/d)</p> </li> <li> <p>Any adverse events</p> <ol id="CD007477-list-0006"> <li> <p>raised levels of creatinine or kidney failure (above upper normal limit or rise of more than 20% above baseline level) </p> </li> <li> <p>skin rash</p> </li> <li> <p>gastrointestinal disturbances</p> </li> <li> <p>neutropenia or agranulocytosis (absolute neutrophil count (ANC) less than 1000/µl or less than 500/µl) </p> </li> <li> <p>raised levels of liver enzymes (above upper normal limit or raise of more than 20% above baseline level) or progression to liver fibrosis </p> </li> <li> <p>hearing loss</p> </li> <li> <p>eye problems (e.g. retinal toxicity)</p> </li> <li> <p>unanticipated adverse events as reported in the primary studies</p> </li> </ol> </li> <li> <p>Participant satisfaction (measured e.g. by questionnaire) and compliance with chelation treatment (measured by the number of people in each arm that show adequate level of adherence to treatment (intake or application of iron chelator on five or more days per week). </p> </li> <li> <p>Cost of intervention per year.</p> </li> </ol> </p> <p>For future updates, data from outcomes not defined a priori but which arise from the review will be collected, if the outcome is considered to be of clinical relevance. </p> </section> </section> </section> <section id="CD007477-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>No language restriction was applied.</p> <section id="CD007477-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We identified relevant studies from the Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register using the terms: (sickle cell OR haemoglobinopathies general) AND ICL670(A). </p> <p>The Haemoglobinopathies Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of <i>The Cochrane Library</i>) and quarterly searches of MEDLINE. Unpublished work is identified by searching the abstract books of five major conferences: the European Haematology Association conference; the American Society of Haematology conference; the British Society for Haematology Annual Scientific Meeting; the Caribbean Health Research Council Meetings; and the National Sickle Cell Disease Program Annual Meeting. For full details of all searching activities for the register, please see the relevant section of the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/CF/frame.html" target="_blank">Cochrane Cystic Fibrosis and Genetic Disorders Group Module</a>. </p> <p>Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 13 March 2014. </p> <p>For this current, updated version, the following additional databases were searched in July 2012 and again in August 2013 (see <a href="./appendices#CD007477-sec-0090">Appendix 1</a>; <a href="./appendices#CD007477-sec-0091">Appendix 2</a> for details): MEDLINE; MEDLINE In‐Process; MEDLINE Daily Update; PubMed (limited to “Epub ahead of print”); Embase; Embase Alert; <i>The Cochrane Library</i> (Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials (Central), Other Reviews (DARE), Methods Studies, Technology Assessments, Economic Evaluations, Cochrane Groups Issue); Biosis Previews; ISI Web of Science; Derwent Drug File; XTOXLINE. </p> <p>An RCT filter was used for searches in MEDLINE, Embase, Biosis Previews, ISI Web of Science, Derwent Drug File and XTOXLINE. Also, the search was limited to reports published in between 2009 and 2012 (search undertaken in July 2012) and to reports published between 2012 and 2013 (search undertaken in August 2013). </p> <p>Since deferasirox treatment is an intervention where there is still ongoing research, the following four trial registries were searched on 03 June 2013 for all years available in all possible fields using the basic search function (using separately the following keyword terms; 'deferasirox', 'exjade', 'ICL670', 'ICL 760', 'CGP72670' and 'CGP 72670'): </p> <p> <ol id="CD007477-list-0007"> <li> <p>Current Controlled Trials Register ‐ via <a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a>; (all available registers were searched); </p> </li> <li> <p>ClinicalTrials.gov ‐ via <a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>; </p> </li> <li> <p>ICTRP ‐ via <a href="http://www.who.int./ictrp/en/" target="_blank">www.who.int./ictrp/en/</a>; </p> </li> <li> <p>Deutsches Register klinischer Studien DRKS (German Clinical Trials Register) ‐ via <a href="http://www.drks.de" target="_blank">www.drks.de</a>. </p> </li> </ol> </p> <p>For the previous version of this review, in addition to the register search, several databases and ongoing trial registers were searched. See <a href="./appendices#CD007477-sec-0092">Appendix 3</a> for full details. </p> </section> <section id="CD007477-sec-0039"> <h4 class="title">Searching other resources</h4> <p>Reference lists of all identified papers were screened additionally to identify other potentially relevant citations. </p> <p>Contact was made with selected experts in the field as well as the manufacturer of deferasirox (Novartis) to request information on unpublished studies that involved deferasirox. </p> </section> </section> <section id="CD007477-sec-0040"> <h3 class="title" id="CD007477-sec-0040">Data collection and analysis</h3> <section id="CD007477-sec-0041"> <h4 class="title">Selection of studies</h4> <p>One author (JM) screened all titles and abstracts of papers identified by the search strategies for relevance. We only excluded citations which were clearly irrelevant at this stage. We obtained full copies of all potentially relevant papers. At this stage two review authors (JM and DB) independently screened the full papers, identified relevant studies and assessed eligibility of studies for inclusion. We resolved any disagreement on the eligibility of studies through discussion and consensus, or if necessary through a third party (GA). We excluded all irrelevant records and recorded details of the studies and the reasons for exclusion. </p> </section> <section id="CD007477-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Aside from details relating to the risk of bias of the included studies, we extracted two groups of data. </p> <p> <ol id="CD007477-list-0008"> <li> <p>Study characteristics: place of publication; date of publication; population characteristics; setting; detailed nature of intervention; detailed nature of comparator; and detailed nature of outcomes. A key purpose of this data was to define unexpected clinical heterogeneity in included studies independently from the analysis of the results. </p> </li> <li> <p>Results of included studies with respect to each of the main outcomes indicated in the review question. We carefully recorded reasons why an included study did not contribute data on a particular outcome and considered the possibility of selective reporting of results on particular outcomes. </p> </li> </ol> </p> <p>Two review authors (JM, DB) independently undertook data extraction using a data extraction form developed by the authors. The review authors resolved any disagreements by consensus or through discussion with a third author (GA). Once disagreements had been resolved, we recorded the extracted data on the final data extraction form. One review author (JM) transcribed these into RevMan 5.2 (<a href="./references#CD007477-bbs2-0072" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">Review Manager 2012</a>). Another review author (DB, LS) verified all data entry for discrepancies. </p> </section> <section id="CD007477-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (JM, DB) assessed every study using a simple form and followed the domain‐based evaluation as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> 5.0 (<a href="./references#CD007477-bbs2-0041" title="HigginsJPT , Altman DG(editors) . Chapter 8: Assessing risk of bias in included studies. In: In: The Cochrane LibraryI42TCC editor(s). In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org. Chichester, UK: John Wiley &amp; Sons, Ltd, 2008. ">Higgins 2008a</a>). </p> <p>We assessed the following domains as having either a low, unclear or high risk of bias: </p> <p> <ol id="CD007477-list-0009"> <li> <p>randomisation;</p> </li> <li> <p>concealment of allocation;</p> </li> <li> <p>blinding (of participants, personnel and outcome assessors);</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting;</p> </li> <li> <p>other sources of bias.</p> </li> </ol> </p> <p>We reviewed the assessments and discussed any inconsistencies between the review authors in the interpretation of inclusion criteria and their significance to the selected studies. We resolved any disagreements through discussion with a third author (GA). We did not automatically exclude any study as a result of a rating of an 'unclear' or 'high' risk of bias. We present the evaluation of the risk of bias of the included studies in tabular form in the <a href="./full#CD007477-sec-0052">Results</a> section of the review. </p> </section> <section id="CD007477-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed extracted data using the most up‐to‐date version of RevMan available at the time of analysis (<a href="./references#CD007477-bbs2-0072" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">Review Manager 2012</a>). </p> <p>We planned to extract hazard ratios with their 95% confidence intervals (CI) for the time‐to‐event outcomes mortality and end‐organ damage. If hazard ratios were not given, we planned to use indirect estimation methods described by Parmar (<a href="./references#CD007477-bbs2-0065" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>) and Williamson (<a href="./references#CD007477-bbs2-0088" title="WilliamsonPR , SmithCT , HuttonJL , MarsonAG . Aggregate data meta‐analysis with time‐to‐event outcomes. Statistics in Medicine2002;21(22):3337‐51. ">Williamson 2002</a>) to calculate them. </p> <p>Since we were unable to either extract these data from the study reports or receive the necessary information from the primary investigators, as an alternative we used the proportions of participants with the respective outcomes measured at certain time points (i.e. three months, six months, then six‐monthly intervals) to be able to calculate risk ratios (RR). </p> <p>We expressed any results for binary outcomes as RR with 95% CIs as measures of uncertainty. Continuous outcomes were expressed as mean differences (MD) with 95% CIs as measures of uncertainty. </p> </section> <section id="CD007477-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>We did not include any cross‐over studies nor non‐inferiority studies. Therefore, the following methods of analysis were not used for this current version of the review. However, for future updates, when conducting a meta‐analysis combining results from cross‐over studies, we plan to use the methods recommended by Elbourne (<a href="./references#CD007477-bbs2-0028" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). For combining parallel and cross‐over studies, we will use the methods described by Curtin (<a href="./references#CD007477-bbs2-0021" title="CurtinF , AltmanDG , ElbourneD . Meta‐analysis combining parallel and cross‐over clinical trials. I: Continuous outcomes. Statistics in Medicine2002;21(15):2131‐44. ">Curtin 2002a</a>; <a href="./references#CD007477-bbs2-0022" title="CurtinF , ElbourneD , AltmanDG . Meta‐analysis combining parallel and cross‐over clinical trials. II: Binary outcomes. Statistics in Medicine2002;21(15):2145‐59. ">Curtin 2002b</a>; <a href="./references#CD007477-bbs2-0023" title="CurtinF , ElbourneD , AltmanDG . Meta‐analysis combining parallel and cross‐over clinical trials. III: The issue of carry‐over. Statistics in Medicine2002;21(15):2161‐73. ">Curtin 2002c</a>). </p> <p>For some outcomes, a possible perception of the comparison might be whether deferasirox is not inferior to standard treatment with deferoxamine. Therefore, a per‐protocol analysis would be of interest, as is often used for non‐inferiority studies, for our primary outcome as well as for the groups one to five of our secondary outcomes. </p> <p>Studies included in future versions of this review may report information concerning the intention‐to‐treat (ITT) or per protocol (PP) population or both which we would analyse according to Witte who lists several proposals for analysing these, depending on the data available (<a href="./references#CD007477-bbs2-0089" title="WitteS , VictorN . Some problems with the investigation of noninferiority in meta‐analysis. Methods of Information in Medicine2004;43(5):470‐4. ">Witte 2004</a>). </p> <p> <ol id="CD007477-list-0010"> <li> <p>If all studies report only an ITT analysis (or all studies report only a PP analysis), we will perform a non‐inferiority meta‐analysis based on Witte's `perfect case' proposal. </p> </li> <li> <p>If some studies report only an ITT analysis and others only a PP analysis (exclusively), we will perform meta‐regression with analysis type as a covariate. </p> </li> <li> <p>If some studies report only an ITT analysis and others only a PP analysis, whilst others report both, we will undertake a sensitivity analysis. </p> </li> <li> <p>If all studies give enough information to do both analyses, we will analyse a bivariate model. </p> </li> </ol> </p> <p>For time‐to‐event data, we would state non‐inferiority if the relative difference in hazard ratios is less than 10%. For RRs, we would define non‐inferiority as a RR difference of less than 10% in treatment failures compared to standard therapy. For the continuous outcomes of 'measures of iron overload and iron excretion' as well as 'costs' we would also consider a relative difference of 10% as equivalent. </p> </section> <section id="CD007477-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We requested any missing data from the original investigators.</p> </section> <section id="CD007477-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>For outcomes for which both studies provided data, we assessed heterogeneity using Chi<sup>2</sup> and quantified it by using the I<sup>2</sup> statistic (<a href="./references#CD007477-bbs2-0039" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. ">Higgins 2002</a>; <a href="./references#CD007477-bbs2-0040" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). This measure describes the percentage of total variation across studies that is caused by heterogeneity rather than by chance (<a href="./references#CD007477-bbs2-0040" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). The values of I<sup>2</sup> lie between 0% and 100%. We used a simplified categorization of heterogeneity with the following categories: low (I<sup>2</sup> less than 30%); moderate (I<sup>2</sup> between 30% to 60%); and high (I<sup>2</sup> more than 60%) (<a href="./references#CD007477-bbs2-0025" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: In: The Cochrane LibraryI42TCC editor(s). In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org. Chichester, UK: John Wiley &amp; Sons, Ltd, 2008. ">Deeks 2008</a>). We considered heterogeneity to be significant when the P value of Chi<sup>2</sup> was less than 0.1. </p> <p>In future updates of this review, if moderate or high heterogeneity is detected and far more than the present two studies are included (i.e. 10 or more studies), we intend to explore clinical heterogeneity by examining differences between groups as detailed below (<a href="#CD007477-sec-0050">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> <section id="CD007477-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>We made a great effort to minimise the likelihood of publication bias by the use of a comprehensive search strategy including the search of abstracts and contacting the manufacturer of deferasirox. We did not use funnel plots to assess publication bias, since asymmetry is difficult to detect with a small number of studies (i.e. less than 10) and we could only include two studies in this updated version of the review. If in future we will be able to include more than 10 studies in this review, we will use funnel plots to graphically assess the likelihood of publication bias. We took care in translating the results of the included studies into recommendations for action by involving all review authors in drawing conclusions. </p> </section> <section id="CD007477-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We conducted meta‐analyses using a fixed‐effect model as the primary analysis. If we found marked clinical, methodological or statistical heterogeneity (I<sup>2</sup> more than 30%), we performed a secondary analysis using a random‐effects model and reported results from both models. </p> </section> <section id="CD007477-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did not perform subgroup analyses as outlined in our protocol since only two studies could be included. For the same reason investigation of clinical or methodological heterogeneity was not done. However, for future updates of this review, we plan to assess clinical heterogeneity by examining differences due to: </p> <p> <ul id="CD007477-list-0011"> <li> <p>age of participants (i.e., 0 to 2 years; 3 to 5 years; 6 to 11 years; 12 to 17 years; 18 years or older); </p> </li> <li> <p>age at commencement of the intervention (i.e., 0 to 2 years; 3 to 5 years; 6 to 11 years; 12 to 17 years; 18 years or older); </p> </li> <li> <p>baseline measures of iron overload (i.e. LIC (mg Fe/g dw): ≤3; &gt;3 to ≤ 7; &lt; 7 to ≤ 14; &lt; 14 or serum ferritin (ng/mL (or both)): &lt; 1000; &gt; 1000 to ≤ 2500; &gt; 2500 to ≤ 4000; &gt; 4000). </p> </li> </ul> </p> <p>Subgroup analyses are planned for different:</p> <p> <ul id="CD007477-list-0012"> <li> <p>doses of intervention (≤ 10 mg/kg; &gt; 10 to ≤ 20 mg/kg; &gt; 20 to ≤ 30 mg/kg; &gt; 30 mg/kg);</p> </li> <li> <p>genotypes of SCD (e.g. HbSS, HbS/β‐Thal or HbSC).</p> </li> </ul> </p> </section> <section id="CD007477-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses based on assessment of risk of bias and publication status (unpublished and published studies) were not performed since only two studies could be included in this review. However, for future updates of this review we plan to investigate the robustness of our results through a sensitivity analysis on the basis of the risk of bias of the included studies by defining the following groups: low risk of bias (successful blinding of patients, people involved in treatment and care and outcome assessors; adequate allocation concealment; loss to follow‐up of less than 20%); high risk of bias (no blinding, inadequate allocation concealment and loss to follow‐up of more than 20%); unclear risk of bias (rating of unclear risk of bias in at least one of these three categories). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007477-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007477-sec-0052"></div> <section id="CD007477-sec-0053"> <h3 class="title">Description of studies</h3> <section id="CD007477-sec-0054"> <h4 class="title">Results of the search</h4> <p>The updated searches for this current version of the review (run in July 2012 and again in August 2013) identified 715 citations, including 253 duplicates (<a href="#CD007477-fig-0001">Figure 1</a>). The title and abstract screening of the remaining 462 citations identified 25 as potentially eligible for this review. The full text screening excluded 24 citations for the following reasons: </p> <div class="figure" id="CD007477-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram combining first search &amp; update searches (most recent search of databases: August 2013; most recent search of the Cochrane CFGD Group's Trials Register: 13 March 2014)" data-id="CD007477-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram combining first search &amp; update searches (most recent search of databases: August 2013; most recent search of the Cochrane CFGD Group's Trials Register: 13 March 2014) </p> </div> </div> </div> <p> <ul id="CD007477-list-0013"> <li> <p>review or editorial/comment or other form of published article (N = 7);</p> </li> <li> <p>other intervention not including deferasirox (N = 1);</p> </li> <li> <p>observational data on people with SCD (N = 14);</p> </li> <li> <p>cost‐effectiveness analyses on people with SCD (N = 1);</p> </li> <li> <p>RCT (SWiTCH trial) comparing hydroxyurea and phelobotomy to transfusions and chelation (chelation group included three patients on deferoxamine) (N = 1). </p> </li> </ul> </p> <p>The identified abstract described a study which was labelled as ongoing in the previous version of our review (<a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). By ascertaining that this study had been completed by May 2011, further data listed on ClinicalTrials.gov, could be included in our analysis. </p> <p>In addition, search of the Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register identified a full‐text journal article to this study published after our electronic search was run (<a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). We added the additional data given in the published paper to our review (in addition to the data given in the ClinicalTrials.gov entry) and ascertained that no inconsistencies were to be found. </p> <section id="CD007477-sec-0055"> <h5 class="title">Previous searches</h5> <p>In August 2009, a search of eligible trials was undertaken for the previous version of the review. A total of 420 citations were identified, including 221 duplicates. The title and abstract screening of the 199 unique citations identified 62 as potentially eligible for this review. However, after full text screening no additional reports could be included. Reasons for exclusions were: </p> <p> <ul id="CD007477-list-0014"> <li> <p>included people with other disease than SCD (thalassaemia (N = 27), myelodysplastic syndrome (N = 14), or other conditions (N = 4)) </p> </li> <li> <p>review or editorial/comment or other form of published article (N = 5)</p> </li> <li> <p>observational data on people with SCD (N = 12)</p> </li> </ul> </p> <p>The initial search for the previous version of this review, was run on 15 August 2008 and identified 1177 citations, including 648 duplicates. The title and abstract screening of the 529 unique citations identified 153 as potentially eligible for this review. The full text screening excluded 147 citations for any of the following reasons: </p> <p> <ul id="CD007477-list-0015"> <li> <p>included people with other disease than SCD (thalassaemia (N = 72), myelodysplastic syndrome (N = 24) or other conditions (N = 5)) </p> </li> <li> <p>review or editorial/comment or other form of published article (N = 31)</p> </li> <li> <p>other intervention not including deferasirox (N = 1)</p> </li> <li> <p>observational data on people with SCD (N = 12)</p> </li> <li> <p>cost‐effectiveness analyses on people with SCD (N = 2)</p> </li> </ul> </p> <p>For the previous version of this review, we identified six references reporting on a single study (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>) (<a href="#CD007477-fig-0002">Figure 2</a>).This RCT compared deferasirox with deferoxamine. These six reports specifically describe the RCT phase of the study (<a href="./references#CD007477-bbs2-0077" title="VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11, Part 1:95A. ">Vichinsky 2005b</a>; <a href="./references#CD007477-bbs2-0078" title="VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11, Part 1:656A‐7A. ">Vichinsky 2005c</a>; <a href="./references#CD007477-bbs2-0079" title="VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 April 8‐12; Memphis, USA.2006:Abstract no: 175. ">Vichinsky 2006a</a>; <a href="./references#CD007477-bbs2-0080" title="VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 April 8‐12; Memphis, USA2006:Abstract no: 174. ">Vichinsky 2006b</a>; <a href="./references#CD007477-bbs2-0081" title="VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] ">Vichinsky 2007a</a>; <a href="./references#CD007477-bbs2-0083" title="VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2008a</a>). Of these six reports, two were published as full text articles (<a href="./references#CD007477-bbs2-0081" title="VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] ">Vichinsky 2007a</a>; <a href="./references#CD007477-bbs2-0083" title="VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2008a</a>) and four as abstracts (<a href="./references#CD007477-bbs2-0077" title="VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11, Part 1:95A. ">Vichinsky 2005b</a>; <a href="./references#CD007477-bbs2-0078" title="VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11, Part 1:656A‐7A. ">Vichinsky 2005c</a>; <a href="./references#CD007477-bbs2-0079" title="VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 April 8‐12; Memphis, USA.2006:Abstract no: 175. ">Vichinsky 2006a</a>; <a href="./references#CD007477-bbs2-0080" title="VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 April 8‐12; Memphis, USA2006:Abstract no: 174. ">Vichinsky 2006b</a>). The remaining five reports listed under the Vichinsky study ID (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>) report on the extension phases of four clinical trials including patients with SCD, thalassaemia, myelodysplastic syndrome (MDS) and other transfusion‐dependent anemias (<a href="./references#CD007477-bbs2-0015" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11, Part 2:16B. ">Cappellini 2007b</a>; <a href="./references#CD007477-bbs2-0016" title="CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11, Part 1:816A. ">Cappellini 2007c</a>; <a href="./references#CD007477-bbs2-0068" title="PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11, Part 1:815A. ">Piga 2007</a>; <a href="./references#CD007477-bbs2-0082" title="VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11, Part 1:995A. ">Vichinsky 2007b</a>; <a href="./references#CD007477-bbs2-0084" title="VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. ">Vichinsky 2008b</a>). The described total groups (consisting of the deferasirox groups of two observational studies and/or the primary deferasirox group(s) and the cross‐over groups, i.e. patients switching to deferasirox after finishing the two primary randomised studies) only contain patients treated with deferasirox. There are no data presented of the initial control groups receiving deferoxamine. Therefore, the data presented are only observational data of a deferasirox group without a control group. </p> <div class="figure" id="CD007477-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007477-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <p>Thus, a total of two studies were included in this updated version of our review (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>; <a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). </p> </section> </section> <section id="CD007477-sec-0056"> <h4 class="title">Included studies</h4> <p>Two studies including 203 and 212 people, respectively, with SCD met the inclusion criteria (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>; <a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). </p> <section id="CD007477-sec-0057"> <h5 class="title">Vichinsky 2007</h5> <p>This study randomised 203 eligible people in a 2:1 ratio to receive either deferasirox or deferoxamine. The randomisation was performed using an interactive voice response system and was stratified according to the following age groups: 2 years to under 6 years; 6 years to under 12 years; 12 years to under 16 years and 16 years and older. The randomisation sequence included permuted block groups of six patients for each of the four age strata. </p> <p>Only 195 of the 203 randomised patients received treatment and were included in the analysis. Patient characteristics were similar in both groups (<a href="#CD007477-tbl-0002">Table 1</a>). Drug dosing was stratified according to baseline liver iron concentration (LIC) into four groups, with baseline LIC: </p> <div class="table" id="CD007477-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included patients (Vichinsky 2007)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Deferasirox</b> </p> <p><b>(n = 132)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Deferoxamine</b> </p> <p><b>(n = 63)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All patients</b> </p> <p><b>(n = 195)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Age, years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Range</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 ‐ 54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 ‐ 51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 ‐ 54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Age group, # of patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 6 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (4.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (3.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 to &lt; 12 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (22.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (23.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (23.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 to &lt; 16 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33 (25.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (20.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 (23.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 to &lt; 50 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63 (47.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 (49.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94 (48.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 to &lt; 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sex, # of patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 (60.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 (55.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115 (59.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 (39.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (44.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 (41.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Race, # of patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Caucasian</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (6.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (4.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (5.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118 (89.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59 (93.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>177 (90.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (3.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ferritin, μg/l</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3'460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2'834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3'298</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Range</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1'082 ‐ 12'901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1'015 ‐ 15'578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1'015 ‐ 15'578</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline ALT, # of patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 2.5 ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110 (83.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58 (92.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>168 (86.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2.5 ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (15.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (7.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 (13.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Missing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>History of HAV and/or HBV, # of patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Present</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (7.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (6.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (7.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122 (92.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59 (93.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>181 (92.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prior chelation therapy, # of patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deferoxamine or deferiprone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83 (62.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (60.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121 (62.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No prior chelation therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49 (37.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (39.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 (37.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Blood transfusions during study (units of packed RBCs)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Range</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 ‐ 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 ‐ 22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 ‐ 24</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ALT: alanine aminotransferase</p> <p>HAV: hepatitis A virus</p> <p>HBV: hepatitis B virus</p> <p>RBCs: red blood cells</p> <p>ULN: upper limit of normal</p> </div> </div> <p> <ol id="CD007477-list-0016"> <li> <p>≤ 3 mg Fe/g dry weight (dw);</p> </li> <li> <p>&gt; 3 to 7 mg Fe/g dw;</p> </li> <li> <p>&gt; 7 to14 mg Fe/g dw;</p> </li> <li> <p>&gt; 14 mg Fe/g dw.</p> </li> </ol> </p> <p>For the reported LIC values a correction factor of 3.33 and for the adjusted LIC values a correction factor of 6.66 was used to convert the wet weight to dry weight values (<a href="./references#CD007477-bbs2-0009" title="BrittenhamGM , FarrellDE , HarrisJW , FeldmanES , DanishEH , MuirWA , et al. Magnetic‐susceptibility measurement of human iron stores. New England Journal of Medicine. 1982/12/30 1982; Vol. 307, issue 27:1671‐5. [0028‐4793: (Print)] ">Brittenham 1982</a>; <a href="./references#CD007477-bbs2-0062" title="OlivieriNF , BrittenhamGM . Iron‐chelating therapy and the treatment of thalassemia. Blood1997;89(3):739‐61. ">Olivieri 1997</a>). </p> <p>Deferasirox was given once daily each morning as a dispersed solution in water, half‐an‐hour before breakfast. The dosing algorithm according to baseline LIC and average daily doses administered are described in an additional table (<a href="#CD007477-tbl-0003">Table 2</a>). </p> <div class="table" id="CD007477-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Dosing algorithm according to LIC groups and average daily doses administered (Vichinsky 2007)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Baseline LIC (mg Fe / g dw)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline LIC group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>≤ 3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>&gt; 3 ‐ ≤ 7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>&gt; 7 ‐ ≤ 14</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>&gt; 14</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Deferasirox (n = 132)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(n = 4)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(n = 64)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(n = 46)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(n = 18)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol assigned dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported mean LIC ± SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 ± 0.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9 ± 5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.8 ± 1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.5 ± 3.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted mean LIC ± SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.0 ± 0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.8 ± 11.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.6 ± 3.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.0 ± 6.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deferasirox dose (mg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5 ± 3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.0 ± 3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.7 ± 2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.0 ± 2.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Min ‐ Max deferasirox dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.0 ‐ 12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4 ‐ 23.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.0 ‐ 24.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.8 ‐ 30.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Deferoxamine (n = 63)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(n = 6)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(n = 21)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(n = 20)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(n = 16)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol assigned dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 ‐ 30 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 ‐ 35 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 ‐ 50 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 50 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported mean LIC ± SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9 ± 3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.2 ± 2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.6 ± 3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.3 ± 5.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted mean LIC ± SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.8 ± 7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.4 ± 4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.2 ± 6.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.6 ± 10.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deferoxamine dose (mg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.9 ± 3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.7 ± 3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.6 ± 9.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.0 ± 7.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Min ‐ Max deferoxamine dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.0 ‐ 29.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.6 ‐ 34.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.0 ‐ 52.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.4 ‐ 62.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deferasirox / Deferoxamine dose ratio</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 : 2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 : 2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 : 1.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 : 1.8</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>dw: dry weight<br/> FE: iron<br/> LIC: liver iron concentration<br/> SD: standard deviation </p> </div> </div> </section> <section id="CD007477-sec-0058"> <h5 class="title">Vichinsky 2011</h5> <p>The second study enrolled 212 patients who were randomised 2:1 to receive either deferasirox (20 mg/kg/day) or deferoxamine (175 mg/kg/week) for 24 weeks. No information regarding randomisation procedure was given in the abstract nor on ClinicalTrials.gov. After 24 weeks, the patients receiving deferoxamine were crossed over to receive deferasirox for the remaining 80 weeks; we therefore limited our analysis to the data available at 24 weeks. </p> <p>Of the 212 included patients, 9 patients were excluded due to GCP violations and a further 12 patients did not receive the study drug deferoxamine. Therefore, only data on a group of 191 patients were provided in the available abstract and on clinicaltrials.gov. Patient characteristics were similar in both groups (<a href="#CD007477-tbl-0004">Table 3</a>). </p> <div class="table" id="CD007477-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of included patients (Vichinsky 2011)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Deferasirox (n = 135)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Deferoxamine (n = 68)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All Patients (n = 203)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Age, years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean ± Standard deviation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.4 ± 10.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.2 ± 10.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.3 ± 10.23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age group, # patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 to &lt; 6 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (4.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 to &lt; 12 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 (31.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (30.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63 (31.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 to &lt; 16 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 (25.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (26.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53 (26.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 to &lt; 50 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (37.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (35.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 (36.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 to &lt; 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>= 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Gender, # patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56 (41.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33 (48.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89 (43.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79 (58.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 (51.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114 (56.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Race, # patients (5)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Caucasian</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130 (96.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65 (95.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>195 (96.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oriental</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (2.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (3.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Weight group, # patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 15 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 to &lt; 35 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (28.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 (33.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 (30.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 to &lt; 55 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43 (31.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (26.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (30.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55 to &lt; 75 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 (31.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (32.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64 (31.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=75 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (7.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (6.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Missing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (2.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>History of splenectomy, #patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (16.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (14.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (15.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113 (83.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58 (85.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>171 (84.2 )</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serum ferritin, ng/mL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.a.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Range</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>920 ‐ 12535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1178 ‐ 16535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.a.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serum ferritin category, # of patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 1000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (2.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1000 ‐ ≤ 2500 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 (25.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (41.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 (30.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2500 ‐ ≤ 4000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (33.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (23.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (30.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 4000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 (38.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (35.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76 (37.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Transfusional iron intake, mL RBC/kg/day</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.a.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Range</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1 ‐ 2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.1 ‐ 0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.a.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose of iron chelating drug, mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Planned dose (mg/kg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.8 (2.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.1 (4.6) *</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.a.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Received dose (mg/kg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.6 (2.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.1 (4.7) *</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.a.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* based on dose per day over 5 days/week<br/> RBC: red blood cells </p> </div> </div> </section> </section> <section id="CD007477-sec-0059"> <h4 class="title">Excluded studies</h4> <p>Our search identified one RCT comparing alternative treatment (hydroxyurea and phlebotomy) to standard treatment (transfusions and chelation) (<a href="./references#CD007477-bbs2-0003" title="AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutic Phlebotomy in Children with Sickle Cell Anemia, Stroke, and Iron Overload: The SWiTCH Experience. Blood2011; Vol. 118, issue 21:481‐2. KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012; Vol. 87, issue 2:221‐3. WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWITCH). Blood2012;119(17):3925‐32. ">Ware 2011</a>). This trial did not fulfil our stated inclusion criteria and we therefore decided to exclude this study. </p> </section> </section> <section id="CD007477-sec-0060"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias of the included studies according to the six categories outlined in <a href="#CD007477-sec-0043">Assessment of risk of bias in included studies</a>. Our interpretation of the published reports of the two studies is as follows (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>; <a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). </p> <p>See the risk of bias graph (<a href="#CD007477-fig-0002">Figure 2</a>) and risk of bias summary (<a href="#CD007477-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD007477-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007477-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD007477-sec-0061"> <h4 class="title">Allocation</h4> <section id="CD007477-sec-0062"> <h5 class="title">Randomisation</h5> <p>Both studies do not describe the method of randomisation. However, the allocation is characterized as 'randomised'. Therefore, the risk of bias rating for both studies is 'unclear'. </p> </section> <section id="CD007477-sec-0063"> <h5 class="title">Concealment of allocation</h5> <p>One study used an interactive voice response system; we therefore assumed that adequate allocation concealment was achieved and rated its risk of bias as 'low' (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>). The risk of bias for the second study was concluded to be 'unclear' as this domain was not discussed (<a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). </p> </section> </section> <section id="CD007477-sec-0064"> <h4 class="title">Blinding</h4> <p>The included studies are classified as open‐label trials. There is no mention of blinding. Therefore the risk of bias is high for both studies (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>; <a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). </p> </section> <section id="CD007477-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <p>The first Vichinsky study included 203 patients, but only 195 received treatment and were included in the safety population (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>). Reasons for this are not stated. Additionally, a similar percentage of patients of both groups (11.4% of the deferasirox group and 11.1% of the deferoxamine group) either discontinued treatment due to adverse events (5.3% on deferasirox and 3.2% on deferoxamine) or were lost to follow up (two patients from the deferasirox group, one patient from the deferoxamine group), withdrew consent (six patients from the deferasirox group, one patient from the deferoxamine group) or were excluded due to protocol violations (three patients from the deferoxamine group). No intention‐to‐treat analysis with regard to efficacy was performed. Data are only presented as <i>per protocol</i> although the actual numbers of patients analysed is not very clearly stated. Therefore, we assessed this study as having a high risk of bias for this domain. </p> <p>In the second Vichinsky study, 212 patients were originally included. Nine participants from one site were excluded due to severe 'Good Clinical Practice' (GCP) violations (<a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). Only 191 of the remaining 203 patients received treatment and were considered for analysis, i.e. 12 out of 68 are missing in the deferoxamine group at 24 weeks. For efficacy analysis (serum ferritin) 18 patients in deferasirox and 6 patients in deferoxamine were not considered. Therefore, we assessed this study as having a high risk of bias for this domain. </p> </section> <section id="CD007477-sec-0066"> <h4 class="title">Selective reporting</h4> <p>According to the methods section of the first Vichinsky study, ferritin values were monitored monthly, clinical and laboratory assessments were performed for safety reasons at 12, 24 and 36 weeks; LIC was also determined by SQUID at 24 weeks (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>). These data are not reported. Also, it is unclear whether other possible outcomes were measured but not reported. We did not have any access to the original trial protocols to evaluate this. We contacted the corresponding author, but did not receive a response to our inquiry. Therefore, the risk of bias rating for this study is high risk. </p> <p>The second study provided detailed outcome data on clinicaltrials.gov (<a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). Therefore, we assessed this study as having a low risk of bias for this domain. </p> </section> <section id="CD007477-sec-0067"> <h4 class="title">Other potential sources of bias</h4> <p>Both studies were sponsored by Novartis. A potential influence of the manufacturer of deferasirox on the reporting of the results can not be excluded due to the cooperation between Novartis staff and the investigators. Therefore the risk of bias rating is unclear for both studies. </p> </section> </section> <section id="CD007477-sec-0068"> <h3 class="title" id="CD007477-sec-0068">Effects of interventions</h3> <p>See: <a href="./full#CD007477-tbl-0001"><b>Summary of findings for the main comparison</b> Deferasirox versus deferoxamine for managing transfusional iron overload in people with sickle cell disease</a> </p> <p>Only two studies are included in this review. Thus, sensitivity analyses, subgroup analyses or assessments of heterogeneity were not undertaken for this version of the review. </p> <section id="CD007477-sec-0069"> <h4 class="title">Primary outcome</h4> <section id="CD007477-sec-0070"> <h5 class="title">1. Overall mortality</h5> <p>There were only limited data available on the primary outcome: the second Vichinsky trial reported one death in the deferasirox group (assessed as unrelated to the study drug) and no deaths in the deferoxamine group, resulting in a relative risk of 1.26 (95% CI 0.05 to 30.41) (<a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). The interpretation of this analysis is hampered by this study's short follow up. The first Vichinsky trial did not report whether any deaths had occurred (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>). </p> </section> </section> <section id="CD007477-sec-0071"> <h4 class="title">Secondary outcomes</h4> <section id="CD007477-sec-0072"> <h5 class="title">1. Reduced end‐organ damage due to iron deposition</h5> <p>There were no data available on cardiac failure or histological evidence of hepatic fibrosis. One study reported on incidence of type 2 diabetes mellitus: one patient in the deferasirox group and no patient in the deferoxamine group contracted diabetes (<a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). This difference is not significant, RR 1.26 (95% CI 0.05 to 30.41) (<a href="./references#CD007477-fig-0005" title="">Analysis 1.2</a>). No other data were available on endocrine disease. </p> <p>Elevated liver function tests (LFTs) (alanine transaminase (ALT) ≥ 5x upper normal limit (UNL) on two consecutive visits), reported in two studies, were observed in five and two patients, respectively, treated with deferasirox and no patients on deferoxamine, although the difference was not significant, RR 3.66 (95% CI 0.47 to 28.65) (<a href="./references#CD007477-fig-0006" title="">Analysis 1.3</a>) (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>; <a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). The second study reported on the number of patients in each group with abnormal liver function tests: 2 patients and 0 patients in the deferasirox group and in the deferoxamine group, respectively (no significant difference), RR 2.10 (95% CI 0.10 to 42.97) (<a href="./references#CD007477-fig-0007" title="">Analysis 1.4</a>) (<a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). However, since no definition of the event 'liver function test abnormal' was given, we did not pool these data with the first study. </p> <p>No information was available on the surrogate markers elevated fasting glucose; pathological oral glucose tolerance test; or pathological measures in echocardiography. </p> </section> <section id="CD007477-sec-0073"> <h5 class="title">2. Measures of iron overload</h5> <p>Ferritin reduction was greater in people treated with deferoxamine at the end of the two studies (12 months and 24 weeks, respectively). These results were statistically significant with a MD of change of 440.69 µg/l in favour of deferoxamine (95% CI 11.73 to 869.64) (<a href="./references#CD007477-fig-0008" title="">Analysis 1.5</a>) (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>; <a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). However, only data on 83 out of 132 (62.9%) and 117 out of 135 (86.7%) patients, respectively, treated with deferasirox and 33 out of 63 (52.4%) and 50 out of 56 (89.3%), respectively, treated with deferoxamine were available according to the study authors. </p> <p>Liver tissue iron assessment by SQUID, reported in one study (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>), showed no statistically significant difference for the overall group of patients, MD ‐0.20 mg Fe/g dw (95% CI ‐3.15 to 2.75) (<a href="./references#CD007477-fig-0009" title="">Analysis 1.6</a>), nor for the subgroup of patients receiving simple transfusions, MD ‐0.20 mg Fe/g dw (95% CI ‐1.97 to 1.57) (<a href="./references#CD007477-fig-0010" title="">Analysis 1.7</a>). For the subgroup of patients receiving exchange transfusions, the deferasirox‐treated patients showed a higher, statistically significant reduction in LIC, MD ‐5.20 mg Fe/g dw (95% CI ‐8.56 to ‐1.84) (<a href="./references#CD007477-fig-0010" title="">Analysis 1.7</a>). Neither results of LIC from liver biopsies nor from MRI assessment were available. </p> </section> <section id="CD007477-sec-0074"> <h5 class="title">3. Measures of iron excretion (urine and/or faeces) over 24 hours</h5> <p>There were no data available on iron excretion in urine or faeces.</p> </section> <section id="CD007477-sec-0075"> <h5 class="title">4. Adverse events</h5> <p>Except for occurrence of serum creatinine values exceeding the upper limit of normal (ULN) and alanine aminotransferase levels &gt; 5x ULN, the first Vichinsky study did not report on rare adverse events (frequency of less than 10%) (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>); according to the ClinicalTrials.gov entry, the second study reported only on adverse events occurring in more than 5% of participants, while no such threshold was chosen for serious adverse events (<a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). </p> <p>Creatinine levels were reported by the first Vichinsky study and partly also by the second Vichinsky study (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>; <a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). Mild stable increases in creatinine were observed more often (though not statistically significant) in patients treated with deferasirox, RR 1.64 (95% CI 0.98 to 2.74) (<a href="./references#CD007477-fig-0011" title="">Analysis 1.8</a>); the mean increase in creatinine over the course of the study was 3.24 µmol/l, significantly higher in the deferasirox‐treated group (95% CI 0.45 to 6.03) (<a href="./references#CD007477-fig-0012" title="">Analysis 1.9</a>). However, no statistically significant difference was seen in frequency of increases &gt; UNL of creatinine (reported by two studies), RR 0.72 (95% CI 0.12 to 4.18) (<a href="./references#CD007477-fig-0011" title="">Analysis 1.8</a>). </p> <p>Adverse events of any kind were reported significantly more often in the deferoxamine group, RR 0.88 (95% CI 1.03 to 5.55) (<a href="./references#CD007477-fig-0013" title="">Analysis 1.10</a>) (<a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). However, no difference was observed regarding the incidence of serious adverse events. They occurred with similar frequency in both groups (<a href="./references#CD007477-fig-0013" title="">Analysis 1.10</a>). Also, the difference in serious adverse events suspected to be related to the study drug did not reach significance (<a href="./references#CD007477-fig-0013" title="">Analysis 1.10</a>). </p> <p>Rash occurred significantly more often in the deferasirox group, RR 2.39 (95% CI 1.03 to 5.55) (<a href="./references#CD007477-fig-0013" title="">Analysis 1.10</a>). Gastrointestinal adverse effects such as abdominal pain, nausea, vomiting or diarrhoea were collected separately, so the overall proportion of patients experiencing gastrointestinal side effects can not be given. Statistically significant differences in favour of deferoxamine were observed regarding the adverse events: diarrhoea, RR 3.09 (95% CI 1.53 to 6.26); and nausea, RR 2.06 (95% CI 1.11 to 3.80) (<a href="./references#CD007477-fig-0013" title="">Analysis 1.10</a>). There were no data available regarding the frequency of neutropenia or agranulocytosis, nor regarding the occurrence of hearing problems or eye problems. Further adverse events are described in another graph; no additional statistically significant differences were observed (<a href="./references#CD007477-fig-0013" title="">Analysis 1.10</a>). The mean growth velocity in cm per year, reported in one study, was about 1 cm higher in the deferasirox group; however, these differences were not statistically significant for any of the analysed age groups (<a href="./references#CD007477-fig-0015" title="">Analysis 1.12</a>). </p> <p>Available data for five adverse events showed marked heterogeneity (I<sup>2</sup> more than 30%) and were analysed additionally with a random‐effects model, in accordance with our pre‐defined analysis plan as described in <a href="#CD007477-sec-0047">Assessment of heterogeneity</a> (<a href="./references#CD007477-fig-0014" title="">Analysis 1.11</a>). These analyses provided similar results. </p> </section> <section id="CD007477-sec-0076"> <h5 class="title">5. Participant satisfaction</h5> <p>Participant satisfaction was reported by the first Vichinsky study (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>). Both satisfaction with treatment, RR 3.13 (95% CI 1.99 to 4.93) and convenience of this treatment, RR 3.85 (95% CI 2.28 to 6.47) were significantly better with deferasirox compared to deferoxamine (<a href="./references#CD007477-fig-0016" title="">Analysis 1.13</a>; <a href="./references#CD007477-fig-0017" title="">Analysis 1.14</a>). Also, the likelihood of continuing chelation therapy estimated by the patients themselves was significantly higher with deferasirox, RR 6.86 (95% CI 3.38 to 13.91) (<a href="./references#CD007477-fig-0018" title="">Analysis 1.15</a>). These effects were also reflected by the overall rate of discontinuations, RR 0.53 (95% CI 0.31 to 0.92), but not by the rate of discontinuations due to adverse effects, RR 1.03 (95% CI 0.29 to 3.63)) (<a href="./references#CD007477-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD007477-sec-0077"> <h5 class="title">6. Cost of intervention per year</h5> <p>The included studies provided no data on the cost of either intervention (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>; <a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007477-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007477-sec-0078"></div> <p>This review is aimed at determining the effectiveness and safety of deferasirox for the management of iron overload in people with SCD. </p> <p>Firstly, we planned to compare deferasirox to either no treatment or placebo. However, no study addressing this question could be identified, which is not surprising considering that the necessity of chelation therapy in iron‐overloaded people is well‐established and, if at all, only short‐term, e.g. pharmacokinetic studies, would be ethically justifiable. Longer‐term studies comparing deferasirox with no therapy or placebo would not suffice the paradigm of equipoise and would therefore be unethical. </p> <p>Secondly, comparisons with other iron chelating regimens were planned. Only two studies comparing deferasirox with deferoxamine treatment could be identified (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>; <a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). </p> <section id="CD007477-sec-0079"> <h3 class="title" id="CD007477-sec-0079">Summary of main results</h3> <p>Two trials, involving 203 and 212 people, respectively, compared the efficacy and safety of deferasirox and deferoxamine after 12 months and 24 weeks, respectively. The primary outcome of the included studies was safety and tolerability; efficacy was only addressed as a secondary endpoint. Thus, only limited data were available for most of our pre‐specified patient‐important long‐term efficacy outcomes. One study reported on our primary outcome (mortality). However, follow up was too short to allow valid conclusions on mortality to be drawn. Also, only limited data were available for reduced end‐organ damage (incidence of diabetes mellitus). In a five‐year extension phase, three deaths assessed as unrelated to the study drug occurred; surrogate markers of end‐organ damage were also reported. However, it has to be kept in mind that observational data are less reliable than randomised controlled trial data and thus should be interpreted with caution (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>). </p> <p>Two additional efficacy outcomes we were planning to analyse were addressed in the included studies, namely the surrogate marker serum ferritin (addressed in both included studies) and LIC measured by SQUID (addressed in one study). Serum ferritin reduction was greater with deferoxamine with a mean difference of change of 440.69 µg/l (95% CI 11.73 to 869.64). Deferasirox was effective in reducing LIC; however, there was no statistically significant difference in LIC reduction between deferasirox and deferoxamine for the overall group of patients adjusted for transfusion category, MD ‐0.20 mg Fe/g dw (95% CI ‐3.15 to 2.75) (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>). However, based on the results from one large phase III trial including 586 people with thalassaemia, deferasirox presumably offers a similar efficacy as deferoxamine (<a href="./references#CD007477-bbs2-0013" title="CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. [PUBMED: 16352812] ">Cappellini 2006</a>), in particular if higher doses of deferasirox are used. </p> <p>Adverse events were observed frequently in both groups. Statistically significant differences in the frequency between the deferasirox‐ and the deferoxamine‐treated groups were encountered for rash, diarrhoea and nausea in favour of deferoxamine, and for adverse events of any kind in favour of deferasirox. The mean increase of creatinine was also significantly higher with deferasirox, although the clinical relevance is debatable. Further differences in the potential for adverse effects between deferasirox and deferoxamine could not be detected, although the data suggest differences, e.g. with regard to growth velocity in favour of deferasirox, probably due to the sample size of the reporting study. Long‐term adverse events were not recorded in either of the included studies. Also, it should be stressed that the investigators of the 2007 trial reported only adverse events that occurred in at least one treatment group with a frequency of more than 10% (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>). Therefore, in this particular study, no information regarding potentially rarer adverse events such as kidney failure, agranulocytosis or eye and hearing problems in people with SCD was reported (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>). The later trial reported only on adverse events occurring in more than 5% of participants, while no such threshold was established for serious adverse events (<a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>). Since both cataracts or lenticular opacities and hypoacusis or neurosensory deafness have been reported in less than 1% of patients in the phase III trial of thalassaemia patients, regular screening at 12‐month intervals is advised. Also, periodic monitoring of serum creatinine and liver function test on a monthly basis is recommended. </p> <p>As one would expect, satisfaction with, and convenience of, deferasirox treatment was significantly higher; the same advantage of deferasirox was observed in an ancillary study to the phase III trial with thalassaemia patients (<a href="./references#CD007477-bbs2-0014" title="CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. [PUBMED: 17697909] ">Cappellini 2007a</a>). These effects were reflected by the overall rate of discontinuations, which were significantly higher in the deferoxamine group. </p> <p>However, it remains unclear whether compliance with deferasirox will exceed compliance achieved with deferoxamine in the long term, which is of paramount importance to prevent morbidity and mortality in people with secondary iron overload (<a href="./references#CD007477-bbs2-0024" title="DeSanctisV , RoosM , GasserT , FortiniM , RaiolaG , GalatiMC . Impact of long‐term iron chelation therapy on growth and endocrine functions in thalassaemia. Journal of pediatric endocrinology &amp; metabolism : JPEM2006;19(4):471‐80. [PUBMED: 16759032] ">De Sanctis 2006</a>; <a href="./references#CD007477-bbs2-0090" title="WolfeL , OlivieriN , SallanD , ColanS , RoseV , PropperR , et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. New England Journal of Medicine1985;312(25):1600‐3. [PUBMED: 4000198] ">Wolfe 1985</a>). </p> </section> <section id="CD007477-sec-0080"> <h3 class="title" id="CD007477-sec-0080">Overall completeness and applicability of evidence</h3> <p>The aim of this review, namely to assess the efficacy and safety of deferasirox in the treatment of people with SCD and secondary iron overload, could only be partly accomplished. Due to limitations in data from only two studies with both a relatively short follow up and a small number of participants (12 months, 195 participants and 24 weeks, 203 participants, respectively), it is difficult to arrive at unambiguous conclusions. The available data, as well as data from studies in people with thalassaemia, show that deferasirox is effective in reducing iron overload. However, whether deferasirox is more effective than deferoxamine could not be shown; our data actually suggest that deferoxamine is more effective (as measured by serum ferritin) based on the appropriate ratio of doses of deferasirox and deferoxamine used in these two studies. It could be argued that there is no need for deferasirox to be more efficacious since equivalent effectiveness in conjunction with better compliance and a more favourable safety profile could well be a huge improvement for affected patients. For this reason, the only completed phase III trial in people with thalassaemia was designed and analysed as a non‐inferiority trial (<a href="./references#CD007477-bbs2-0013" title="CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. [PUBMED: 16352812] ">Cappellini 2006</a>). </p> <p>This review, based on the two relatively small included studies, was not able to address some patient‐important outcomes such as mortality or end‐organ damage in sufficient detail to allow clear conclusions to be drawn, since these events are very rare and therefore the detection of statistically significant differences in studies of this size is unlikely. Given RCTs, large enough to detect these events, are unlikely to be conducted, further large observational studies will need to provide the main evidence for decision‐making. Therefore, recommendations regarding the choice of iron chelating treatment in people with SCD can only be based on limited evidence. While there is indirect evidence from studies of patients with thalassaemia, it can not necessarily be assumed that for example, the safety profile will be exactly the same in people with SCD compared to people with thalassaemia. </p> </section> <section id="CD007477-sec-0081"> <h3 class="title" id="CD007477-sec-0081">Quality of the evidence</h3> <p>There is only limited evidence on the effects of deferasirox in people with SCD. Only two studies were available for inclusion in this review. Only 195 participants of the initially 203 eligible patients and 191 of initially 212 eligible patients, respectively, were included in the safety analysis. The proportion of patients included in the <i>per protocol</i> efficacy analyses ranged from 57.1% for serum ferritin to 85.2% for LIC measured by SQUID (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>). The reasons for this are not stated. The overall risk of bias of the included studies was moderate and is described in detail in the risk of bias tables (<a href="./references#CD007477-sec-0098" title="">Characteristics of included studies</a>). Participants were not blinded to treatment due to the different modes of application of deferasirox and deferoxamine. However, blinding of assessors would have been feasible and could have improved the quality of some rather subjective outcomes, e.g. some adverse events such as nausea or abdominal pain. Finally, it is noted that both studies included in this review were sponsored by Novartis, the manufacturer of deferasirox. In the past, studies conducted with pharmaceutical company involvement in other therapeutic areas have been shown to contain a bias towards the drugs of the sponsor (<a href="./references#CD007477-bbs2-0007" title="BhandariM , BusseJW , JackowskiD , MontoriVM , SchunemannH , SpragueS , et al. Association between industry funding and statistically significant pro‐industry findings in medical and surgical randomized trials. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2004;170(4):477‐80. [PUBMED: 14970094] ">Bhandari 2004</a>). </p> </section> <section id="CD007477-sec-0082"> <h3 class="title" id="CD007477-sec-0082">Potential biases in the review process</h3> <p>A very comprehensive search strategy was applied to identify all potential studies and their reports. Despite identifying 12 reports (including 9 abstracts) of a single RCT (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>) and also a full paper, an abstract, and data reported on clinicaltrials.gov for a further RCT (<a href="./references#CD007477-bbs2-0002" title="Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients. http://clinicaltrials.gov/ct2/show/results/NCT00110617 (accessed 01 February 2014). VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]. Blood2011;118(21):497. VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068‐73. ">Vichinsky 2011</a>), data for several relevant outcomes pre‐specified in our protocol were not available. Several of these outcome measures are, however, important when making an informed and balanced decision on choice of chelator. While it is likely that some of these outcomes were not measured during the trial, others might have been collected but not reported. Unfortunately, even after contacting the primary investigators, we have not been able to obtain any additional data to date. </p> <p>To minimize bias in the process of doing this review, we followed the rigid methodology for systematic reviews as outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007477-bbs2-0042" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley &amp; Sons, 2008. ">Higgins 2008b</a>). </p> </section> <section id="CD007477-sec-0083"> <h3 class="title" id="CD007477-sec-0083">Agreements and disagreements with other studies or reviews</h3> <p>A review based on a systematic literature search focusing on deferasirox was published in 2006 (<a href="./references#CD007477-bbs2-0075" title="VanOrdenHE , HagemannTM . Deferasirox‐‐an oral agent for chronic iron overload. Annals of Pharmacotherapy2006;40(6):1110‐7. [PUBMED: 16735647] ">VanOrden 2006</a>). In addition to data from a phase III trial, the 2006 review included evidence from phase I and phase II studies, as well as from pharmacokinetic studies, in both humans and non‐humans. However, since the studies on patients with SCD included in this review was not yet published, their review did not include any data from a RCT of patients with SCD. Most of the patients included in the 2006 review had thalassaemia and approximately three‐quarters of these patients are from a single phase III RCT. The authors made no attempt to pool the data; so findings are presented narratively (including observational data). The authors concluded that their findings suggest that deferasirox is as safe and effective as deferoxamine. However, further studies would be needed to assess its efficacy in other transfusion‐requiring diseases such as SCD. </p> <p>A further systematic review published in 2007 summarized the available data from five phase I and II and one phase III study (<a href="./references#CD007477-bbs2-0053" title="LindseyWT , OlinBR . Deferasirox for transfusion‐related iron overload: a clinical review. Clinical therapeutics2007;29(10):2154‐66. [PUBMED: 18042472] ">Lindsey 2007</a>). All six studies are critically discussed, but no data were pooled and only synthesized qualitatively. Based on the only trial looking at efficacy as a primary endpoint (<a href="./references#CD007477-bbs2-0013" title="CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. [PUBMED: 16352812] ">Cappellini 2006</a>), the authors came to the conclusion that the two agents had similar efficacy although, overall the non‐inferiority of deferasirox could not be shown by the primary phase III study investigators. Tolerability was assessed as good, even though deferasirox was associated with a higher incidence of adverse effects. The authors concluded that long‐term efficacy and safety remained to be established. </p> <p>In 2009 a comprehensive health technology assessment on deferasirox for secondary iron overload in patients with chronic anaemia, such as thalassemia and SCD was published (<a href="./references#CD007477-bbs2-0056" title="McLeodC , FleemanN , KirkhamJ , BagustA , BolandA , ChuP , et al. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technology Assessment (Winchester, England)2009;13(1):iii‐iv, ix‐xi, 1‐121. [PUBMED: 19068191] ">McLeod 2009</a>). It identified 14 RCTs looking at various iron chelation regimens with a high degree of heterogeneity between trials in terms of trial design and outcome reporting. Only three of these compared deferasirox to deferoxamine, none of them contained data that could be included in a meta‐analysis. Furthermore, eight economic evaluations were included in their report. The authors concluded that there appeared to be little difference between agents in terms of reducing serum ferritin. The economic evaluations appeared to demonstrate the cost‐effectiveness of deferasirox compared to deferoxamine. However, the authors stated that both their clinical and economic analyses were restricted by the available evidence and should only be considered as exploratory. </p> <p>Additionally, several narrative reviews on deferasirox have been published over recent years ( <a href="./references#CD007477-bbs2-0011" title="BrittenhamGM . Iron‐chelating therapy for transfusional iron overload. New England Journal of Medicine2011;364(2):146‐56. ">Brittenham 2011</a>; <a href="./references#CD007477-bbs2-0017" title="CappelliniMD . Long‐term efficacy and safety of deferasirox. Blood Reviews2008;22 Suppl 2:S35‐41. [PUBMED: 19059055] ">Cappellini 2008</a>; <a href="./references#CD007477-bbs2-0018" title="CappelliniMD , PattoneriP . Oral iron chelators. Annual Review of Medicine2009;60:25‐38. [PUBMED: 19630568] ">Cappellini 2009</a>; <a href="./references#CD007477-bbs2-0037" title="GalanelloR , CampusS , OrigaR . Deferasirox: pharmacokinetics and clinical experience. Expert Opinion on Drug Metabolism &amp; Toxicology2012;8(1):123‐34. ">Galanello 2012</a>; <a href="./references#CD007477-bbs2-0085" title="WalterPB , HarmatzP , VichinskyE . Iron metabolism and iron chelation in sickle cell disease. Acta Haematologica2009;122(2‐3):174‐83. [PUBMED: 19907155] ">Walter 2009</a>). </p> <p>A review published in 2011 evaluated different chelation treatments in sickle cell anaemia, including deferasirox, regarding their effectiveness, safety and costs (<a href="./references#CD007477-bbs2-0054" title="LucaniaG , VitranoA , FilosaA , MaggioA . Chelation treatment in sickle‐cell anaemia: much ado about nothing?. British Journal of Haematology2011;154(5):545‐55. ">Lucania 2011</a>). Based on one RCT (<a href="./references#CD007477-bbs2-0001" title="CappelliniMD , VichinskyE , FordJM , RabaultB , PorterJ . Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) &lt;= 1000 ng/mL in long‐term studies. Blood2007; Vol. 110, issue 11 Pt 2:16B. CappelliniMD , VichinskyE , GalanelloR , PigaA , WilliamsonP , PorterJB . Long‐term treatment with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, is effective in patients with transfusion‐dependent anemias. Blood2007; Vol. 110, issue 11 Pt 1:816A. PigaA , VichinskyE , ForniGL , KilincY , MaserukaH , KattamisA . Long‐term efficacy and safety with deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in pediatric patients. Blood2007; Vol. 110, issue 11 Pt 1:815A. VichinskyE . Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA2006:Abstract no: 174. VichinskyE . Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract]. 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8‐12; Memphis, USA.2006:Abstract no: 175. VichinskyE , BernaudinF , ForniGL , GardnerR , HassellK , HeeneyMM , et al. Long‐term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease. British Journal of Haematology2011;154(3):387‐97. VichinskyE , CoatesT , ThompsonAA , BernaudinF , RodriguezM , RojkjaerL , et al. Deferasirox (Exjade (R)), the Once‐Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5‐Year Follow‐up. Blood2008;112(11):506. VichinskyE , CoatesTD , ThompsonAA , MuellerBU , LagroneD , HeeneyMM . Long‐term efficacy and safety of deferasirox (Exjade (R), ICL670), a once‐daily oral iron chelator, in patients with sickle cell disease (SCD). Blood2007; Vol. 110, issue 11 Pt 1:995A. VichinskyE , FischerR , FungE , OnyekwereO , PorterJ , SwerdlowP , et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once‐daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden. Blood2005; Vol. 106, issue 11 Pt 1:95A. VichinskyE , FischerR , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO). Blood2005; Vol. 106, issue 11 Pt 1:656A‐7A. VichinskyE , OnyekwereO , PorterJ , SwerdlowP , EckmanJ , LaneP , et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology2007;136(3):501‐8. [PUBMED: 17233848] VichinskyE , PakbazZ , OnyekwereO , PorterJ , SwerdlowP , CoatesT , et al. Patient‐reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open‐label phase II trial. Acta Haematologica2008;119(3):133‐41. [PUBMED: 18408362] ">Vichinsky 2007</a>), two prospective cohort studies (<a href="./references#CD007477-bbs2-0019" title="CappelliniMD , PorterJ , El‐BeshlawyA , LiCK , SeymourJF , ElalfyM , et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion‐dependent anemias. Haematologica2010;95(4):557–66. ">Cappellini 2010</a>; <a href="./references#CD007477-bbs2-0071" title="RaphaelJL , BernhardtMB , MahoneyDH , MuellerBU . Oral iron chelation and the treatment of iron overload in a pediatric hematology center. Pediatric Blood &amp; Cancer2009;52(5):616–20. ">Raphael 2009</a>) and one case report (<a href="./references#CD007477-bbs2-0092" title="YusufB , McPhedranP , BrewsterUC . Hypocalcemia in a dialysis patient treated with deferasirox for iron overload. American Journal of Kidney Diseases2008;52(3):587–90. ">Yusuf 2008</a>) in people treated with deferasirox, the authors concluded that deferasirox was effective and seemed to be as safe as deferoxamine. However, the authors stated that follow up was too short to judge treatment with deferasirox as completely safe; and concerns about patients with possible pre‐existing renal impairment should be emphasized. The overall conclusion by the authors was that chelation treatment in SCD, even though widely recommended and practised, had been based on little efficacy and safety evidence. According to this review, the cost‐benefit ratio had also not been fully explored. </p> <p>An economic evaluation in 2009 reported that deferasirox resulted in US$3197 savings compared to deferoxamine with a gain of 2.63 quality‐adjusted life‐years per patient (<a href="./references#CD007477-bbs2-0047" title="KimJ , KimY . A time‐cost augmented economic evaluation of oral deferasirox versus infusional deferoxamine [corrected] for patients with iron overload in South Korea. Value in Health2009;12(Suppl 3):S78‐81. ">Kim 2009</a>). We were unable to assess the costs of treatment with deferasirox since no data were reported in the included studies. </p> <p>Finally, several reports have recently raised concerns about the safety of deferasirox and possible toxic side effects. Kontoghiorghes summarized several reports on mortality caused by deferasirox, with one study giving a 11.7% mortality rate (1935 of 16514 patients) (<a href="./references#CD007477-bbs2-0051" title="KontoghiorghesGJ . Turning a blind eye to deferasirox's toxicity?. Lancet2013;381(9873):1183–4. ">Kontoghiorghes 2013</a>). An observational study reported that nine out of 10 observed patients presented at least one sign of proximal tubular dysfunction at a mean (SD) of 17.2 (8.9) months after initiation of deferasirox therapy (<a href="./references#CD007477-bbs2-0027" title="DubourgL , LaurainC , RanchinB , PondarreC , Hadj‐AissaA , Sigaudo‐RousselD , et al. Deferasirox‐induced renal impairment in children: an increasing concern for pediatricians. Pediatric Nephrology2012;27(11):2115‐22. ">Dubourg 2012</a>). Therefore, a systematic safety review including observational data seemed to be warranted. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007477-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/urn:x-wiley:14651858:media:CD007477:CD007477-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_t/tCD007477-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram combining first search &amp; update searches (most recent search of databases: August 2013; most recent search of the Cochrane CFGD Group's Trials Register: 13 March 2014)" data-id="CD007477-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram combining first search &amp; update searches (most recent search of databases: August 2013; most recent search of the Cochrane CFGD Group's Trials Register: 13 March 2014) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/full#CD007477-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007477-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/urn:x-wiley:14651858:media:CD007477:CD007477-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_t/tCD007477-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007477-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/full#CD007477-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007477-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/urn:x-wiley:14651858:media:CD007477:CD007477-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_t/tCD007477-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007477-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/full#CD007477-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007477-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/urn:x-wiley:14651858:media:CD007477:CD007477-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_t/tCD007477-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Deferasirox versus deferoxamine, Outcome 1 Mortality." data-id="CD007477-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Deferasirox versus deferoxamine, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references#CD007477-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007477-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/urn:x-wiley:14651858:media:CD007477:CD007477-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_t/tCD007477-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Deferasirox versus deferoxamine, Outcome 2 Diabetes mellitus." data-id="CD007477-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Deferasirox versus deferoxamine, Outcome 2 Diabetes mellitus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references#CD007477-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007477-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/urn:x-wiley:14651858:media:CD007477:CD007477-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_t/tCD007477-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Deferasirox versus deferoxamine, Outcome 3 Elevated ALT levels (&gt; 5 UNL) on two consecutive visits." data-id="CD007477-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Deferasirox versus deferoxamine, Outcome 3 Elevated ALT levels (&gt; 5 UNL) on two consecutive visits. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references#CD007477-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007477-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/urn:x-wiley:14651858:media:CD007477:CD007477-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_t/tCD007477-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Deferasirox versus deferoxamine, Outcome 4 Abnormal liver function tests." data-id="CD007477-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Deferasirox versus deferoxamine, Outcome 4 Abnormal liver function tests.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references#CD007477-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007477-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/urn:x-wiley:14651858:media:CD007477:CD007477-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_t/tCD007477-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Deferasirox versus deferoxamine, Outcome 5 Serum ferritin (µg/l)." data-id="CD007477-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Deferasirox versus deferoxamine, Outcome 5 Serum ferritin (µg/l).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references#CD007477-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007477-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/urn:x-wiley:14651858:media:CD007477:CD007477-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_t/tCD007477-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Deferasirox versus deferoxamine, Outcome 6 LIC measured by SQUID Biomagnetometer (mg Fe/g dw); Overall population adjusted for transfusion category." data-id="CD007477-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Deferasirox versus deferoxamine, Outcome 6 LIC measured by SQUID Biomagnetometer (mg Fe/g dw); Overall population adjusted for transfusion category. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references#CD007477-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007477-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/urn:x-wiley:14651858:media:CD007477:CD007477-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_t/tCD007477-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Deferasirox versus deferoxamine, Outcome 7 LIC measured by SQUID Biomagnetometer (mg Fe/g dw); Per transfusion category subgroup." data-id="CD007477-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Deferasirox versus deferoxamine, Outcome 7 LIC measured by SQUID Biomagnetometer (mg Fe/g dw); Per transfusion category subgroup. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references#CD007477-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007477-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/urn:x-wiley:14651858:media:CD007477:CD007477-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_t/tCD007477-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Deferasirox versus deferoxamine, Outcome 8 Creatinine increase." data-id="CD007477-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Deferasirox versus deferoxamine, Outcome 8 Creatinine increase.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references#CD007477-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007477-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/urn:x-wiley:14651858:media:CD007477:CD007477-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_t/tCD007477-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Deferasirox versus deferoxamine, Outcome 9 Change in creatinine from baseline (µmol/l)." data-id="CD007477-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Deferasirox versus deferoxamine, Outcome 9 Change in creatinine from baseline (µmol/l). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references#CD007477-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007477-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/urn:x-wiley:14651858:media:CD007477:CD007477-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_t/tCD007477-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Deferasirox versus deferoxamine, Outcome 10 Other adverse events (fixed‐effect model)." data-id="CD007477-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Deferasirox versus deferoxamine, Outcome 10 Other adverse events (fixed‐effect model). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references#CD007477-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007477-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/urn:x-wiley:14651858:media:CD007477:CD007477-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_t/tCD007477-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Deferasirox versus deferoxamine, Outcome 11 Other adverse events (random‐effects model)." data-id="CD007477-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Deferasirox versus deferoxamine, Outcome 11 Other adverse events (random‐effects model). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references#CD007477-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007477-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/urn:x-wiley:14651858:media:CD007477:CD007477-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_t/tCD007477-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Deferasirox versus deferoxamine, Outcome 12 Growth velocity (cm/year)." data-id="CD007477-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Deferasirox versus deferoxamine, Outcome 12 Growth velocity (cm/year).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references#CD007477-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007477-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/urn:x-wiley:14651858:media:CD007477:CD007477-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_t/tCD007477-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Deferasirox versus deferoxamine, Outcome 13 Satisfaction." data-id="CD007477-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Deferasirox versus deferoxamine, Outcome 13 Satisfaction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references#CD007477-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007477-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/urn:x-wiley:14651858:media:CD007477:CD007477-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_t/tCD007477-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Deferasirox versus deferoxamine, Outcome 14 Convenience." data-id="CD007477-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Deferasirox versus deferoxamine, Outcome 14 Convenience.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references#CD007477-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007477-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/urn:x-wiley:14651858:media:CD007477:CD007477-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_t/tCD007477-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Deferasirox versus deferoxamine, Outcome 15 Likelihood of continuing treatment." data-id="CD007477-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Deferasirox versus deferoxamine, Outcome 15 Likelihood of continuing treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references#CD007477-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007477-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/urn:x-wiley:14651858:media:CD007477:CD007477-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_t/tCD007477-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Deferasirox versus deferoxamine, Outcome 16 Discontinuations." data-id="CD007477-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Deferasirox versus deferoxamine, Outcome 16 Discontinuations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references#CD007477-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/media/CDSR/CD007477/image_n/nCD007477-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007477-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Deferasirox versus deferoxamine for managing transfusional iron overload in people with sickle cell disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Deferasirox versus deferoxamine for managing transfusional iron overload in people with sickle cell disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with sickle cell disease and transfusional iron overload<br/> <b>Settings:</b> <br/> <b>Intervention:</b> deferasirox </p> <p><b>Comparison:</b> deferoxamine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Deferoxamine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Deferasirox</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> <br/> Follow up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not estimable (event rate in study 0/56)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not estimable (event rate in study 1/135)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> <br/> (0.05 to 30.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐organ damage (incidence of diabetes)</b> <br/> Follow up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not estimable (event rate in study 0/56)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not estimable (event rate in study 1/135)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> <br/> (0.05 to 30.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LIC measured by SQUID biomagnetometer (mg Fe/g dw); overall population adjusted for transfusion category</b> <br/> Follow up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean LIC measured by SQUID biomagnetometer (mg Fe/g dw) in the intervention group was <b>0.2 lower</b> (3.15 lower to 2.75 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum ferritin (µg/l)</b> <br/> Follow up: 24 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum ferritin (µg/l) in the intervention groups was<br/> <b>440.69 higher</b> <br/> (11.73 to 869.64 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>283<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AE:</b> Change in creatinine from baseline (µmol/l)<br/> Follow up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean creatinine change from baseline in the intervention group was <b>3.24 higher</b> (0.45 to 6.03 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Discontinuations</b> <br/> Follow up: 24 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>168 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> <br/> (52 to 155) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.53</b> <br/> (0.31 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>398<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction</b> <br/> Follow up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>238 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>745 per 1000</b> <br/> (474 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.13</b> <br/> (1.99 to 4.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AE</b> : adverse events; <b>CI:</b> confidence interval; <b>dw</b> : dry weight; <b>Fe</b> : iron; <b>LIC</b> : liver iron concentration; <b>RR:</b> risk ratio; <b>SQUID</b>: superconducting quantum interference device </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> No ITT analysis with regard to efficacy. Unclear risk of other bias due to involvement of sponsor and possibility of selective reporting. See also risk of bias table.<br/> <sup>2</sup> Mortality due to iron overload cannot be adequately assessed in studies with a maximum follow up of 52 weeks.<br/> <sup>3</sup> Wide 95% confidence interval.<br/> <sup>4</sup> Serious inconsistency with an I² of 77%. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Deferasirox versus deferoxamine for managing transfusional iron overload in people with sickle cell disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/full#CD007477-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007477-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included patients (Vichinsky 2007)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Deferasirox</b> </p> <p><b>(n = 132)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Deferoxamine</b> </p> <p><b>(n = 63)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All patients</b> </p> <p><b>(n = 195)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Age, years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Range</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 ‐ 54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 ‐ 51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 ‐ 54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Age group, # of patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 6 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (4.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (3.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 to &lt; 12 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (22.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (23.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (23.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 to &lt; 16 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33 (25.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (20.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 (23.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 to &lt; 50 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63 (47.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 (49.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94 (48.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 to &lt; 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sex, # of patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 (60.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 (55.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115 (59.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 (39.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (44.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 (41.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Race, # of patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Caucasian</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (6.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (4.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (5.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118 (89.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59 (93.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>177 (90.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (3.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ferritin, μg/l</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3'460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2'834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3'298</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Range</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1'082 ‐ 12'901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1'015 ‐ 15'578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1'015 ‐ 15'578</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline ALT, # of patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 2.5 ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110 (83.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58 (92.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>168 (86.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2.5 ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (15.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (7.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 (13.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Missing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>History of HAV and/or HBV, # of patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Present</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (7.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (6.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (7.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122 (92.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59 (93.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>181 (92.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prior chelation therapy, # of patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deferoxamine or deferiprone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83 (62.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (60.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121 (62.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No prior chelation therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49 (37.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (39.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 (37.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Blood transfusions during study (units of packed RBCs)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Range</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 ‐ 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 ‐ 22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 ‐ 24</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>ALT: alanine aminotransferase</p> <p>HAV: hepatitis A virus</p> <p>HBV: hepatitis B virus</p> <p>RBCs: red blood cells</p> <p>ULN: upper limit of normal</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included patients (Vichinsky 2007)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/full#CD007477-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007477-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Dosing algorithm according to LIC groups and average daily doses administered (Vichinsky 2007)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Baseline LIC (mg Fe / g dw)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline LIC group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>≤ 3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>&gt; 3 ‐ ≤ 7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>&gt; 7 ‐ ≤ 14</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>&gt; 14</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Deferasirox (n = 132)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(n = 4)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(n = 64)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(n = 46)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(n = 18)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol assigned dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported mean LIC ± SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 ± 0.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9 ± 5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.8 ± 1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.5 ± 3.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted mean LIC ± SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.0 ± 0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.8 ± 11.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.6 ± 3.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.0 ± 6.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deferasirox dose (mg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5 ± 3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.0 ± 3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.7 ± 2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.0 ± 2.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Min ‐ Max deferasirox dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.0 ‐ 12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4 ‐ 23.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.0 ‐ 24.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.8 ‐ 30.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Deferoxamine (n = 63)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(n = 6)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(n = 21)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(n = 20)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(n = 16)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol assigned dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 ‐ 30 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 ‐ 35 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 ‐ 50 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 50 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported mean LIC ± SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9 ± 3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.2 ± 2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.6 ± 3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.3 ± 5.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted mean LIC ± SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.8 ± 7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.4 ± 4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.2 ± 6.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.6 ± 10.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deferoxamine dose (mg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.9 ± 3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.7 ± 3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.6 ± 9.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.0 ± 7.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Min ‐ Max deferoxamine dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.0 ‐ 29.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.6 ‐ 34.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.0 ‐ 52.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.4 ‐ 62.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deferasirox / Deferoxamine dose ratio</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 : 2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 : 2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 : 1.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 : 1.8</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>dw: dry weight<br/> FE: iron<br/> LIC: liver iron concentration<br/> SD: standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Dosing algorithm according to LIC groups and average daily doses administered (Vichinsky 2007)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/full#CD007477-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007477-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of included patients (Vichinsky 2011)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Deferasirox (n = 135)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Deferoxamine (n = 68)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All Patients (n = 203)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Age, years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean ± Standard deviation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.4 ± 10.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.2 ± 10.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.3 ± 10.23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age group, # patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 to &lt; 6 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (4.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 to &lt; 12 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 (31.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (30.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63 (31.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 to &lt; 16 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 (25.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (26.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53 (26.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 to &lt; 50 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (37.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (35.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 (36.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 to &lt; 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>= 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Gender, # patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56 (41.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33 (48.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89 (43.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79 (58.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 (51.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114 (56.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Race, # patients (5)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Caucasian</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130 (96.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65 (95.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>195 (96.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oriental</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (2.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (3.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Weight group, # patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 15 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 to &lt; 35 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (28.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 (33.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 (30.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 to &lt; 55 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43 (31.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (26.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (30.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55 to &lt; 75 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 (31.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (32.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64 (31.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=75 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (7.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (6.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Missing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (2.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>History of splenectomy, #patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (16.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (14.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (15.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113 (83.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58 (85.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>171 (84.2 )</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serum ferritin, ng/mL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.a.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Range</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>920 ‐ 12535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1178 ‐ 16535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.a.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serum ferritin category, # of patients (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 1000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (2.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1000 ‐ ≤ 2500 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 (25.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (41.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 (30.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2500 ‐ ≤ 4000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (33.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (23.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (30.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 4000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 (38.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (35.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76 (37.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Transfusional iron intake, mL RBC/kg/day</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.a.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Range</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1 ‐ 2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.1 ‐ 0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.a.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose of iron chelating drug, mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Planned dose (mg/kg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.8 (2.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.1 (4.6) *</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.a.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Received dose (mg/kg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.6 (2.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.1 (4.7) *</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.a.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>* based on dose per day over 5 days/week<br/> RBC: red blood cells </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of included patients (Vichinsky 2011)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/full#CD007477-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007477-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Deferasirox versus deferoxamine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Diabetes mellitus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Elevated ALT levels (&gt; 5 UNL) on two consecutive visits <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.66 [0.47, 28.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Abnormal liver function tests <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serum ferritin (µg/l) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>440.69 [11.73, 869.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 LIC measured by SQUID Biomagnetometer (mg Fe/g dw); Overall population adjusted for transfusion category <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 LIC measured by SQUID Biomagnetometer (mg Fe/g dw); Per transfusion category subgroup <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.29 [‐2.85, 0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 receiving simple transfusions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐1.97, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 receiving exchange transfusions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.20 [‐8.56, ‐1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Creatinine increase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Mild stable increases in serum creatinine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.98, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Creatinine exceeding UNL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.12, 4.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Change in creatinine from baseline (µmol/l) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.24 [0.45, 6.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Other adverse events (fixed‐effect model) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.74, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Serious adverse events suspected to be related to study drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [0.19, 14.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Any adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.79, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Adverse events suspected to be related to study drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.57, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Sickle cell anaemia with crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.82, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.58, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.7 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.95, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.8 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [1.11, 3.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.9 Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.66, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.10 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.71, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.11 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [1.53, 6.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.12 Back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [0.87, 3.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.13 Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.45, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.14 Arthralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.63, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.15 Pain in extremity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.62, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.16 Pharyngeal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.55, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.17 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.38, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.18 Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.35, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.19 Nasal congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.18, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.20 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [1.03, 5.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.21 Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.19, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.22 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.50, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.23 Chest pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.34, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.24 Viral infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.14, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.25 Urinary tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.96 [0.47, 134.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.26 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.09, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.27 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.05, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.28 Injection site pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.00, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.29 Cardio‐respiratory arrest</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.05, 30.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Other adverse events (random‐effects model) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.47, 5.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.34, 3.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.85, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.35, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 Pharyngeal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.39, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Growth velocity (cm/year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 &lt; 6 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 6 to &lt; 12 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 12 ‐ 16 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [1.99, 4.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Patients previously on DFO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.56 [2.00, 6.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Patients not on chelation therapy prior to study start</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.47 [1.18, 5.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Convenience <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.85 [2.28, 6.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Patients previously on DFO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.32 [2.19, 8.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Patients not on chelation therapy prior to study start</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.16 [1.40, 7.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Likelihood of continuing treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.86 [3.38, 13.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Patients previously on DFO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.01 [3.16, 20.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Patients not on chelation therapy prior to study start</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.27 [1.79, 15.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Discontinuations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Discontinuations due to AEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.29, 3.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Overall Discontinuations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.31, 0.92]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Deferasirox versus deferoxamine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007477.pub3/references#CD007477-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007477.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007477-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007477-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007477-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007477\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007477\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007477\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007477\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007477\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007477\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007477\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007477\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007477\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007477\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007477\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007477\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007477\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007477\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007477\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007477\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007477\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007477\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007477.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007477.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007477.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007477.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007477.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717596457"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007477.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717596461"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007477.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dbbcb5a819371',t:'MTc0MDcxNzU5Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 